Thiocycloheptyne Derivatives and Uses Thereof
Stable and reactive thiocycloheptine derivatives address the limitations of TMTH by providing effective copper-free click reactions and bioorthogonal chemistry applications in drug delivery systems and biological systems.
Patent Information
- Application Number
- JP2021500928
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-07-13
- Filing Date
- 2019-07-12
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2039-07-12
AI Technical Summary
Existing thiocycloheptine derivatives, particularly 3,3,6,6-tetramethylthiacycloheptyne (TMTH), suffer from instability and difficulty in derivatization, limiting their use in copper-free click reactions and bioorthogonal chemistry applications.
Development of a new class of sulfur-containing thiocycloheptine derivatives, including compounds of formula (I), which are stable and reactive in copper-free click reactions, allowing for derivatization and use in various coupling reactions and systems.
The new thiocycloheptine derivatives exhibit high reactivity and stability, enabling effective use in copper-free click reactions and bioorthogonal chemistry, with applications in drug delivery systems, proteins, and other biological systems.
Smart Images

Figure 0007584400000047 
Figure 0007584400000048 
Figure 0007584400000049
Abstract
Description
[Technical field]
[0001] The present invention relates to novel thiocycloheptyne derivatives, particularly thiacycloalkyne sulfoimine derivatives and their synthesis. The present invention also relates to the use of the novel thiocycloheptyne derivatives in various coupling reactions, such as those involving linkers, drugs and drug delivery systems, proteins, imaging agents, dyes, chromophores, ligands, etc. The present invention further relates to the use of the novel thiocycloheptyne derivatives in copper-free click reactions. The present invention further relates to the use of the novel thiocycloheptyne derivatives in the generation of a wide variety of systems, such as nanoparticles, proteins, hydrogels, liposomes, antibody drug conjugates, drug polymer conjugates, etc., targeting and / or labeling delivery systems. [Background technology]
[0002] Bioorthogonal chemistry is used to investigate biomolecules and physiological processes. Bioorthogonal chemistry is used when other, more conventional research tools or medicines are unavailable or inadequate. Typically, the protocol starts with labeling a target biomolecule in a cell or organism with a bioorthogonal functional group. A probe molecule with a complementary functionality is provided to the system, and a bioorthogonal chemical reaction specifically delivers the probe to the target of interest. It is considered a key element in the further development of this useful technique by allowing kinetic and yield optimization, for example, easier purification. In the past, the strain-promoted cycloaddition reaction of azides with cyclooctynes was found as a well-tolerated bioorthogonal reaction. The strain-promoted cycloaddition reaction of azides with cyclooctynes, also known as Cu-free (or copper-free) click chemistry, was suggested by the classical work of Krebs and Kimling in the 1970s. They observed that, in contrast to unactivated linear alkynes, which undergo 1,3-dipolar cycloaddition with azides only at elevated temperatures, cyclooctyne readily reacts with the same substrates at room temperature. The increased reactivity of cyclooctyne was attributed to ring strain resulting from the deformation of the bond angles of the alkyne.
[0003] Almeida et al. describe a group of cyclooctynes that have been developed over the years and are used in bioorthogonal coupling reactions. Almeida investigated the effect of sulfur in the ring on cyclooctyne activity and synthesized several thiocycloalkynes. The reactivity of 3,3,6,6-tetramethylthiacycloheptyne (TMTH) in cycloaddition reactions was found to be faster than previous cyclooctyne compounds. King et al. described reasonable stability of TMTH only when the sulfur atom was derivatized with benzyl bromide (Non-Patent Document 1). Furthermore, it was difficult to synthesize other derivatives of TMTH, and further derivatization of sulfur proved difficult. Dommerholt et al. have shown that TMTH has low stability and cannot be isolated in pure form (Non-Patent Document 2). Li et al. showed that TMTH is the fastest SPAAC reported to date (Patent Document 3), but could not be labeled to prevent its application in bioorthogonal reactions. [Prior art documents] [Non-patent literature]
[0004] [Non-Patent Document 1] Chem Commun 2102, 48, 9308 [Non-Patent Document 2] NATURE COMMUNICATIONS 2014, 5, 5378, Top Curr Chem (Z) 2016, 374:16 [Non-Patent Document 3] Molecules, 2016, 21, 1393 Summary of the Invention [Problem to be solved by the invention]
[0005] There is a need for novel, readily available, and reactive compounds that utilize the advantages of TMTH in copper-free click reactions with at least similar reactivity in 1,3 dipolar cycloaddition reactions with azides, nitrones, and other 1,3 dipoles for use in copper-free click reactions. [Means for solving the problem]
[0006] The present inventors have discovered a novel class of sulfur-containing cycloalkynes, in particular thiocycloheptynes. The cycloalkynes of the present invention form a new class of compounds that can be used for a variety of wireline purposes, one of which is that they are reactive in copper-free click chemistry.
[0007] In a first aspect, the present invention relates to compounds of formula (I): [ka] n and m are independently 0, 1, or 2, and n+m is 2; X is O or NR 9 and Y is NR 10 and R 1 , R 2 , R 3 , R 4 are independently hydrogen, halogens (F, Cl, Br, I), O, N, P and S, C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl group, The O, N, P and S each independently represent hydrogen, halogen (F, Cl, Br, I), C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Binds to a cycloalkyloxy group, the alkyl group is optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The alkyl group, (hetero)aryl group, alkyl(heteroaryl group) and (hetero)arylalkyl group are independently and optionally C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Substituted by one or more substituents selected from the group consisting of cycloalkyloxy groups, halogens (F, Cl, Br, I), amino groups, oxo groups and silyl groups; the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted; said alkyl, alkoxy, cycloalkyl and cycloalkyloxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The silyl group has the formula (R 11 )3Si-, where R 11 is independent, C 1 ~C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups and C3-C 12 cycloalkyloxy groups; the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkoxy groups are optionally substituted; the alkyl, alkoxy, cycloalkyl and cycloalkyloxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; R 5 , R 6 , R 7 , R 8 are independently hydrogen, halogens (F, Cl, Br, I), O, N, P and S, C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl group, The O, N, P and S each independently represent hydrogen, halogen (F, Cl, Br, I), C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Binds to a cycloalkyloxy group, the alkyl group is optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The alkyl group, (hetero)aryl group, alkyl(hetero)aryl group and (hetero)arylalkyl group are independently optionally selected from C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12Substituted by one or more substituents independently selected from the group consisting of cycloalkyloxy groups, halogens (F, Cl, Br, I), amino groups, oxo groups, and silyl groups; the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted; said alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The silyl group has the formula (R 11 )3Si-, where R 11 is C1~C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups and C3-C 12 cycloalkyloxy groups; the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted; the alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; R 1 and R 7 , R 1 and R 8 , R 2 and R 7 , R 2 and R 8 , R 3 and R 5 , R 3 and R 6 , R 4 and R 5 , and / or R 4 and R6 optionally, independently, form a fused ring system, such as a cycloalkyl-, cyclo(hetero)aryl-, cycloalkyl(hetero)aryl, -cyclo(hetero)arylalkyl system; the alkyl groups of said fused system are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The alkyl group, (hetero)aryl group, alkyl(hetero)aryl group, and (hetero)arylalkyl group of the condensed system are independently and optionally C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl group C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Substituted with one or more substituents independently selected from the group consisting of cycloalkyloxy groups, halogens, amino groups, oxo groups, and silyl groups; the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted; the alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The silyl group has the formula (R 11 )3Si-, R 11 is C1~C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups and C3-C 12 cycloalkyloxy groups; the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted; the alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; R 9 , R 10 are independently hydrogen, halogen (F, Cl, Br, I), R 12 , -CH=C(R 12 )2, -C≡CR 12 , -[C(R 12 )2C(R 12 )2O]qR 12 (q ranges from 1 to 200), -CN, -N3, -NCX, -XCN, -XR 12 , -N(R 12 )2,- + N(R 12 )3, -C(X)N(R 12 )2, -C(R 12 )2XR 12 , -C(X)R 12 , -C(X)XR 12 , -S(O)R 12 , -S(O)2R 12 , -S(O)OR 12 , -S(O)2OR 12 , -S(O)N(R 12 )2, -S(O)2N(R 12 )2, -OS(O)R 12 , -OS(O)2R 12 , -OS(O)OR 12 , -OS(O)2OR 12 , -P(O)(R 12 )(OR 12 ), -P(O)(OR 12 )2, -OP(O)(OR 12 )2, -Si(R 12 )3, -XC(X)R 12 , -XC(X)XR 12 , -XC(X)N(R 12 )2, -N(R 12 )C(X)R 12 , -N(R12 )C(X)XR 12 and -N(R 12 )C(X)N(R 12 ) 2 selected from the group consisting of X is oxygen or sulfur and R 12 are independently hydrogen, halogen (F, Cl, Br, I), C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl groups.
[0008] In a second aspect, the present invention relates to a method for preparing a compound of formula (I), said method comprising the following steps: a. Conversion of the bishydrazone (2) to the iminodidehydrosulfonimino (3). b. The resulting iminodidehydrosulfonimino (3) is isolated.
[0009] In a third aspect, the present invention relates to compounds of formula (I) wherein one atom of the thiocycloheptyne ring adjacent to the X and / or Y and / or S atom is independently bonded to an optional linking group (L) and functional group (Q) to give a compound of formula (III). (Formula (I))-LQ (III) The linking group (L) is absent or is a linear or branched C1-C 24 Alkylene group, C2-C 24 Alkenylene group, C2-C 24 Alkynylene group, C3-C 24 Cycloalkylene group, C5-C 24 Cycloalkenylene group, C5-C 24 Cycloalkynylene group, C7-C 24 Alkyl(hetero)arylene groups, C7-C 24 (Hetero)arylalkylene groups, C5-C 24 (Hetero)arylalkenylene group, C9-C 24 (hetero)arylalkynylene groups; The alkylene group, alkenylene group, alkynylene group, cycloalkylene group, cycloalkenylene group, cycloalkynylene group, alkyl(hetero)arylene group, (hetero)arylalkylene group, (hetero)arylalkenylene group, and (hetero)arylalkynylene group are optional and independently C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C5-C 12 Cycloalkenyl groups, C5-C 12 Cycloalkynyl groups, C8-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Substituted with one or more substituents selected from the group consisting of cycloalkyloxy groups, halogens (F, Cl, Br, I), amino groups, oxo and silyl groups; The silyl group has the formula (R 11 )3Si, R 11 is defined as above, The functional group Q is hydrogen, halogen (F, Cl, Br, I), R 12 , -CH=C(R 12 )2, -C≡CR 12 , -[C(R 12 )2C(R 12 )2O] q R 12 (q ranges from 1 to 200), -CN, -N3, -NCX, -XCN, -XR 12 , -N(R 12 )2,- + N(R 12 )3, -C(X)N(R 12 )2, -C(R 12 )2XR 12 ,-C(X)R 12 ,—C(X)XR 12 ,—S(O)R 12 , -S(O)2R 12 , -S(O)OR 12 , -S(O)2OR 12 , -S(O)N(R12 )2, -S(O)2N(R 12 )2, -OS(O)R 12 , -OS(O)2R 12 , -OS(O)OR 12 , -OS(O)2OR 12 , -P(O)(R 12 )(OR 12 ), -P(O)(OR 12 )2, -OP(O)(OR 12 )2, -Si(R 12 )3, -XC(X)R 12 , -XC(X)XR 12 , -XC(X)N(R 12 )2, -N(R 12 )C(X)R 12 , -N(R 12 )C(X)XR 12 and -N(R 12 )C(X)N(R 12 ) 2 selected from the group consisting of X is oxygen or sulfur and R 12 are independently hydrogen, halogen (F, Cl, Br, I), C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl groups.
[0010] In a further aspect, the present invention provides compounds of formula (I) of the invention, including compounds which are linked at atom X, Y and / or at one atom of the thiocycloheptyne ring adjacent to the S atom, preferably at Y, to an optional linking group (L) and functional group (Q) to give compounds of formula (III). (Formula (I))-LQ (III) where L and Q are as defined above.
[0011] In a further aspect, the present invention relates to a method for coupling a compound of formula (I) or (III) with a compound containing a 1,3-dipole or 1,3 (hetero) diene, preferably wherein the compound containing a 1,3-dipole or 1,3 (hetero) diene is an azide-containing compound, a nitrone-containing compound or a nitrile oxide-containing compound, preferably an azide-containing compound. The coupling of the compound of the present invention with an azide typically results in a triazole. The compound containing a 1,3-dipole or 1,3-(hetero) diene preferably includes a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle and / or a carrier.
[0012] In a further aspect, the present invention relates to a compound comprising a compound of formula (III) as defined herein, wherein the functional group Q is reactive with a molecule of interest, preferably selected from the group consisting of a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle, and a carrier.
[0013] In a further aspect, the present invention relates to methods for the preparation of a wide variety of systems, such as targeted and / or labeled delivery systems, such as nanoparticles, proteins, hydrogels, liposomes, antibody drug conjugates, drug polymer conjugates, etc., wherein (functionalized) compounds of formula (I) or (III) are linked to an azide.
[0014] In a further aspect, the present invention relates to the use of a compound of formula (I) or (III) in a method for coupling two molecules of interest, more particularly to coupling targeted and / or labeled delivery systems such as nanoparticles, proteins, hydrogels, liposomes, antibody drug conjugates, drug polymer conjugates, etc., to one or more of drugs, antibodies, proteins, peptides, ligands, imaging labels, targeting ligands, delivery agents, nanoparticles, and carriers using copper-free click reaction.
[0015] Another embodiment includes a method for preparing a construct comprising a nanoparticle and an active compound selected from the group of a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle, and a carrier, wherein coupling of the nanoparticle with the active compound comprises coupling of a compound of formula (I) or (III) with an azide-containing compound to form a triazole compound.
[0016] In a further aspect, the present invention relates to the use of the compounds of the present invention in a method for coupling two molecules of interest, where the molecules are optionally independently selected from among a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle, and a carrier. Preferably, one of the molecules of interest comprises a cycloalkyne according to the present invention, and the other molecule of interest is a 1,3-dipole or a 1,3-(hetero)diene, preferably an azide, nitrone-containing or nitrile oxide, more preferably an azide-containing compound. The compound comprising a 1,3-dipole or a 1,3-(hetero)diene preferably comprises a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle, and / or a carrier.
[0017] In a further aspect, the present invention relates to a compound of formula (I) as defined herein, wherein the alkyne group is attached to a compound containing a 1,3-dipole or 1,3-(hetero)diene, wherein the compound containing a 1,3-dipole or 1,3-(hetero)diene is preferably an azide-containing compound, a nitrone-containing compound or a nitrile oxide-containing compound, more preferably an azide-containing compound, and preferably the azide-alkyne coupling results in the formation of a triazole compound. The compound containing a 1,3-dipole or 1,3-(hetero)diene preferably comprises a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle and / or a carrier.
[0018] In a further aspect, the present invention relates to a compound comprising a compound of formula (I) as defined herein coupled to a compound comprising a 1,3-dipole or 1,3-(hetero)diene, wherein the alkyne group of the thiocycloheptyne of formula (I) is coupled to a compound comprising a 1,3-dipole or 1,3-(hetero)diene. Preferably, the compound comprising a 1,3-dipole or 1,3-(hetero)diene is an azide-containing compound, a nitrone-containing compound or a nitrile oxide-containing compound, more preferably an azide-containing compound. And, the azide-alkyne coupling preferably results in the formation of a triazole compound. The compound comprising a 1,3-dipole or 1,3-(hetero)diene preferably comprises a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle and / or a carrier.
[0019] In a further aspect, the present invention relates to the use of the compounds according to the invention in bioorthogonal, optionally copper-free, click reactions.Preferably, the compounds of the present invention are coupled to 1,3-dipoles or 1,3-(hetero)dienes, preferably azides, nitrone-containing compounds or nitrile oxides, more preferably azide-containing compounds.Compounds containing 1,3-dipoles or 1,3-(hetero)dienes preferably include drugs, antibodies, proteins, peptides, ligands, imaging labels, targeting ligands, delivery agents, nanoparticles and / or carriers.
[0020] In a further aspect, the present invention relates to the use of the compounds of the present invention in a method of coupling one or more of drugs, antibodies, proteins, peptides, ligands, imaging labels, targeting ligands, delivery agents, nanoparticles, and carriers to nanoparticles using a copper-free click reaction. Preferably, the nanoparticles comprise a cycloalkyne compound of the present invention and the drug, antibody, protein, peptide, ligand, imaging label, targeting ligand, delivery agent, nanoparticle, or carrier comprises a 1,3-dipole or 1,3-(hetero)dienes, preferably azides, nitrone-containing or nitrile oxides, more preferably azides. Alternatively, the drug, antibody, protein, peptide, ligand, imaging label, targeting ligand, delivery agent, nanoparticle, or carrier comprises a cycloalkyne compound of the present invention and the nanoparticle comprises a 1,3-dipole or 1,3-(hetero)dienes, preferably azides, nitrone-containing or nitrile oxides, more preferably azides. [Brief description of the drawings]
[0021] [Figure 1] Bishydrazone 2 analysis data GCMS: Agilent 6890N / Column: RXi-5MS 20m, inner diameter (ID) 180μm, df 0.18μm. Average speed 50cm / s / Carrier gas: He. Initial temperature: 100℃ / Initial time: 1.5min / Solvent delay: 1.3min Heating rate: 75℃ / min, Final temp: 250℃, Final time: 4.5min, Split ratio: 20:1 / Injector temp: 250℃, Injection volume: 1μl. Detection: MSD (EI-positive) / Detection temp: 280℃ / Mass range: 50~550. Detector: FID / Detector temp: 300℃. [Diagram 2]Bishydrazone 2 Analysis Data Bruker Biospin; Pulse sequence: zg30. Relaxation Delay: 1s. Solvent: CDCl3. Temperature: ~298.7411K. Scan number: 16. Frequency: 400.132470966543MHz. Nucleus: 1H. [Diagram 3] [Compound of Example 2] TMTHSI Analysis Data Column: Waters XSelect CSH C18 (30×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: 95% acetonitrile + 5% mM ammonium bicarbonate aqueous solution. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Linear gradient: t=0min 5% A, t=1.6min 98% A, t=3min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000) [Figure 4] [Compound 3 of Example 2] TMTHSI analysis data Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1 s. Solvent: CDCl3. Temperature: ~297.5603 K. Number of scans: 16. Frequency: 400.132470966543 MHz. Nucleus: 1H. [Diagram 5] [Compound 3 of Example 2] TMTHSI analysis data Bruker Biospin GmbH; Pulse sequence method: zgpg30. Wait time: 8s. Solvent: CDCl3. Temperature ~ 300.5658K. Number of scans: 1024. Frequency: 100.622829328806MHz. Nucleus: 13C. [Figure 6] [Compound 3 of Example 2] TMTHSI analysis data Bruker Biospin GmbH; Pulse sequence method: j mode (jmod). Waiting time: 8 s. Solvent: CDCl3. Temperature: ~301.3172 K. Number of scans: 1024. Frequency: 100.6228298028 MHz. Nucleus: 13C. [Figure 7][Compound 4 of Example 3] Analysis data of TMTHSI-Suc-NHS Column: Waters XSelect CSH C18 (30×2.1 mm, 3.5μ). Flow rate: 1 ml / min; Column temperature: 35°C. Eluent A: 0.1% formic acid in acetonitrile. Eluent B: 0.1% formic acid in aqueous solution. Lin. Gradient: t=0min 5% A, t=1.6min 98% A, t=3min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-400 nm). Detection: MSD ESI pos / neg (mass range: 100-1000). Detection: ELSD (Alltech 3300): Gas flow rate 1.5 ml / min, gas temperature: 40°C. [Figure 8] [Compound 4 of Example 3] Analytical data of TMTHSI-Suc-NHS. Bruker Biospin GmbH: Pulse sequence method: zg30. Waiting time: 1s. Solvent: CDCl3. Temperature: ~298.2043K. Number of scans: 16. Frequency: 400.132470966543MHz. Nucleus: 1H. [Figure 9] [Compound 4 of Example 3] Analysis data of TMTHSI-Suc-NHBn Column: Waters XSelect CSH C18 (30×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient t=0min 5% A, t=1.6min 98% A, t=3min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Figure 10] [Compound 4 of Example 3] Analytical data for TMTHSI-Suc-NHBn Bruker Biospin GmbH: Pulse sequence method: zg30. Wait time: 1 s. Solvent: CDCl3. Temperature: ~298.5264 K. Number of scans: 64. Frequency: 400.132470966543 MHz. Nucleus: 1H. [Figure 11][Compound 6 of Example 5] Analysis data of PoC TMTHSI Column: Waters XSelect CSH C18 (30 × 2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25 ° C. Eluent A: 95% acetonitrile + 5% 10 mM ammonium bicarbonate aqueous solution. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t = 0 min 5% A, t = 1.6 min 98% A, t = 3 min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm) Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Figure 12] [Compound 6 of Example 5] Analytical data of PoC TMTHSI Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1 s. Solvent: CDCl3. Temperature: ~297.6677 K. Number of scans: 16. Frequency: 400.132470966543 MHz. Nucleus: 1H. [Figure 13] [Compound 9 of Example 6] Analysis data of PoC TMTHSI-Suc-NHBn Column: Waters XSelect CSH C18 (30×2.1 mm, 3.5μ). Flow rate: 1 ml / min; Column temperature: 35°C. Eluent A: 0.1% formic acid in acetonitrile. Eluent B: 0.1% formic acid in water. Lin. Gradient: t=0min 5% A, t=1.6min 98% A, t=3min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-400 nm). Detection: MSD ESI pos / neg (mass range: 100-1000). Detection: ELSD (Alltech 3300): Gas flow rate 1.5 ml / min. Gas temperature: 40°C. [Figure 14][Compound 9 of Example 6] Analysis data of PoC TMTHSI-Suc-NHBn Column: Waters XSelect CSH C18 (30×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0min 5% A, t=1.6min 98% A, t=3min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Figure 15] [Compound 9 of Example 6] Analytical data for PoC TMTHSI-Suc-NHBn Bruker Biospin GmbH: Pulse sequence method: zg30. Wait time: 1 s. Solvent: CDCl3. Temperature: ~298.097 K. Number of scans: 16. Frequency: 400.132470966543 MHz. Nucleus: 1H. [Figure 16] [Compound 8 of Example 8] TMTHSI-HER2 Analysis Data Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 0.8 ml / min; Column temperature: 25°C. Eluent A: Acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0min 5% A, t=3.5min 98% A, t=3min 98% A. Post time: 2 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Figure 17A] Comparison of the reaction rates of TMTHSI and BCN-OH. TMTHSI (upper curve) is significantly faster than BCN-OH (lower curve). [Figure 17B] Expanded TMTHSI measurements. [Figure 18][Compound 11 of Example 11] LCMS, Mass data of N1-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-N4-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepan-1-ylidene)succinamide Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0 min 5% A, t=3.5 min 98% A, t=3 min 98% A, Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm) Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Figure 19] [Compound 11 of Example 11] NMR data of N1-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-N4-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepan-1-ylidene)succinamide Bruker Biospin GmbH; Pulse sequence method: zg30. Waiting time: 1s. Solvent: CDCl3 Temperature: ~298.9557K. Scan number: 16. Frequency 400.132470966543MHz. Nucleus: 1H. [Figure 20][Compound 12 of Example 12] LCMS, Mass data of 2,5-dioxopyrrolidin-1-yl (3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepan-1-ylidene) carbamate Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0min 5% A, t=1.6min 98% A, t=3min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Figure 21] [Compound 12 of Example 12] NMR data of 2,5-dioxopyrrolidin-1-yl (3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepan-1-ylidene) carbamate Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1s. Solvent: CDCl3. Temperature: ~298.8484K. Scan number: 16. Frequency: 400.132470966543MHz. Nucleus: 1H. [Figure 22] [Compound 14 of Example 14] LCMS, Mass data of 1-(2-(2-hydroxyethoxy)ethyl)-3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)urea Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0 min 5% A, t=1.6 min 98% A, t=3 min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Diagram 23] [Compound 14 of Example 14] NMR data of 1-(2-(2-hydroxyethoxy)ethyl)-3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)urea Bruker Biospin GmbH Pulse sequence method: zg30. Wait time: 1s. Solvent: CDCl3. Temperature: ~299.7071K. Number of scans: 16. Frequency: 400.132470966543MHz. Nucleus: 1H. [Figure 24] [Compound 15 of Example 15]: LCMS, Mass data of methyl 3-(N-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)sulfamoyl)benzoate Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0 min 5% A, t=1.6 min 98% A, t=3 min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Diagram 25] [Compound 15 of Example 15] NMR data of methyl 3-(N-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)sulfamoyl)benzoate Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1s. Solvent: CDCl3. Temperature: ~299.8145K. Scan number: 16. Frequency: 400.132470966543MHz. Nucleus: 1H. [Figure 26][Compound 16 of Example 16] LCMS, Mass data of 3-(N-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)sulfamoyl)benzoic acid Column: Waters XSelect CSH C18 (50x2.1mm 3.5μ). Flow rate: 1ml / min; Column temperature: 25°C. Eluent A: acetonitrile. Eluent B: 10mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0min 5% A, t=1.6min 98% A, t=3min 98% A. Post time: 1.3min. Detection: DAD (220-320nm, 210 and 220nm). Detection: PDA (210-320nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Figure 27] [Compound 16 of Example 16] NMR data of 3-(N-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)sulfamoyl)benzoic acid Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1s. Solvent: CDCl3. Temperature: ~300.1365K. Scan number: 16. Frequency: 400.132470966543MHz. Nucleus: 1H. [Figure 28] [Compound 17 of Example 17] LCMS, Mass data of 3,3,6,6-tetramethyl-1-(methylimino)-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ6-thiepin 1-oxide Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25°C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0min 5% A, t=1.6min 98% A, t=3min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Figure 29][Compound 17 of Example 17] NMR data of 3,3,6,6-tetramethyl-1-(methylimino)-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ6-thiepin 1-oxide Bruker Biospin GmbH; Pulse sequence method: zg30. Waiting time: 1s. Solvent: CDCl3. Temperature: ~300.1365K. Number of scans: 16. Frequency: 400.132470966543MHz. Nucleus: 1H. [Diagram 30] [Compound 18 of Example 18] LCMS, Mass data of methyl 4-((3,3,6,6-tetramethyl-1-(methylimino)-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ6-thiepin-2-yl)methyl)benzoate Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0 min 5% A, t=1.6 min 98% A, t=3 min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Diagram 31] [Compound 18 of Example 18] NMR data of methyl 4-((3,3,6,6-tetramethyl-1-(methylimino)-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ6-thiepin-2-yl)methyl)benzoate Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1 s. Solvent: CDCl3. Temperature: ~299.9218 K. Number of scans: 16. Frequency: 400.132470966543 MHz. Nucleus: 1H. [Diagram 32]LCMS and Mass Data of [Compound 19 of Example 19] Methyl 4-(((3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)amino)methyl)benzoate Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0 min 5% A, t=1.6 min 98% A, t=3 min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Diagram 33] [Compound 19 of Example 19] NMR data of methyl 4-(((3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)amino)methyl)benzoate Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1s. Solvent: CDCl3. Temperature: ~299.9218K. Scan number: 16. Frequency: 400.132470966543MHz. Nucleus: 1H. [Diagram 34] [Compound 13 of Example 13] LCMS, Mass data of 2,2,2-trifluoro-N-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)acetamide Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0 min 5% A, t=1.6 min 98% A, t=3 min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Diagram 35][Compound 13 of Example 13] 2,2,2-trifluoro-N-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)acetamide Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1 s. Solvent: CDCl3. Temperature: ~299.1845 K. Number of scans: 16. Frequency: 400.132470966543 MHz. Nucleus: 1H. [Diagram 36] [Compound 21 of Example 20] LCMS, Mass Data of tert-butyl (2-((2-aminoethyl)disulfanayl)ethyl)carbamate Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0 min 5% A, t=1.6 min 98% A, t=3 min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm. Detection: MSD ESI pos / neg (mass range 100-1000). [Figure 37] [Compound 21 of Example 20] NMR data of tert-butyl (2-((2-aminoethyl)disulfanayl)ethyl)carbamate Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1 s. Solvent: CDCl3. Temperature: ~295.7355 K. Number of scans: 16. Frequency: 400.132470966543 MHz. Nucleus: 1H. [Figure 38][Compound 22 of Example 21] LCMS, Mass data of 2,2-dimethyl-4,13-dioxo-3-oxa-8,9-dithia-5,12-diazahexadecane-16-oic acid Column: Waters XSelect CSH C18 (30×2.1 mm, 3.5μ). Flow rate: 1 ml / min; Column temperature: 35° C. Eluent A: 0.1% formic acid in acetonitrile. Eluent B: 0.1% formic acid in water. Lin. Gradient: t=0min 5% A, t=1.6min 98% A, t=3min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-400 nm). Detection: MSD ESI pos / neg (mass range: 100-1000). Detection: ELSD (Alltech 3300): gas flow rate 1.5 ml / min, gas temperature: 40°C. [Figure 39] [Compound 22 of Example 21] NMR data of 2,2-dimethyl-4,13-dioxo-3-oxa-8,9-dithia-5,12-diazahexadecane-16-oic acid Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1s. Solvent: CDCl3. Temperature: ~295.6282K. Scan number: 16. Frequency: 400.132470966543MHz. Nucleus: 1H. [Diagram 40] [Compound of Example 22] 23] NMR data of 4-((2-((2-aminoethyl)disulfanayl)ethyl)amino)-4-oxobutanoic acid trifluoroacetate. Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1 s. Solvent: MeOD. Temperature: ~298.097 K. Number of scans: 16. Frequency: 400.132470966543 MHz. Nucleus: 1H. [Diagram 41]LCMS, Mass data of [Compound 24 of Example 23] 4-oxo-4-((2-((2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)ureido)ethyl)disulfanayl)ethyl)amino)butanoic acid Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0 min 5% A, t=1.6 min 98% A, t=3 min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Diagram 42] [Compound 24 of Example 23] NMR data of 4-oxo-4-((2-((2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)ureido)ethyl)disulfanayl)ethyl)amino)butanoic acid Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1s. Solvent: CDCl3. Temperature: ~298.097K. Scan number: 16. Frequency: 400.132470966543MHz Nucleus: 1H. [Diagram 43][Compound 25 of Example 24] 2,5-dioxopyrrolidin-1-yl 4-oxo-4-((2-((2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)ureido)ethyl)disulfanayl)ethyl)amino)butanoate LCMS, Mass data Column: Waters XSelect CSH C18 (30×2.1 mm, 3.5μ). Flow rate: 1 ml / min; Column temperature: 35° C. Eluent A: 0.1% formic acid in acetonitrile. Eluent B: 0.1% formic acid in water. Lin. Gradient: t=0min 5% A, t=1.6min 98% A, t=3min 98% 1s. Post time: 1.3min. Detection: DAD (220-320nm, 210 and 220nm). Detection: PDA (210-400nm). Detection: MSD ESI pos / neg (mass range: 100-1000). Detection: ELSD (Alltech 3300): Gas flow rate 1.5ml / min, gas temperature: 40℃. [Diagram 44] [Compound 25 of Example 24] NMR data of 2,5-dioxopyrrolidin-1-yl 4-oxo-4-((2-((2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)ureido)ethyl)disulfanayl)ethyl)amino)butanoate Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1 s. Solvent: CDCl3. Temperature: ~298.097 K. Number of scans: 16. Frequency: 400.132470966543 MHz. Nucleus: 1H. [Diagram 45]LCMS, Mass data of [Compound 30 of Example 29] (S)-15-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-2,2-dimethyl-4,12-dioxo-3,8-dioxa-5,11-diazahexadecane-16-oic acid Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0 min 5% A, t=1.6 min 98% A, t=3 min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Figure 46] [Compound 30 of Example 29] (S)-15-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-2,2-dimethyl-4,12-dioxo-3,8-dioxa-5,11-diazahexadecane-16-oic acid NMR data Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1 s. Solvent: DMSO-d6. Temperature: ~295.7355 K. Scan number: 64. Frequency: 400.132470966543 MHz. Nucleus: 1H. [Figure 47] NMR data of [Compound 31 of Example 30] N2-(4-(((2-amino-4-oxo-3,4-dihydropteridine-6-yl)methyl)amino)benzoyl)-N5-(2-(2-aminoethoxy)ethyl)-L-glutamine Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1 s. Solvent: DMSO-d6. Temperature: ~298.097 K. Number of scans: 64. Frequency: 400.132470966543 MHz. Nucleus: 1H. [Figure 48]LCMS, Mass data of [Compound 32 of Example 31] N2-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzoyl)-N5-(2-(2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)ureido)ethoxy)ethyl)-L-glutamine Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0 min 5% A, t=1.6 min 98% A, t=3 min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Figure 49] [Compound 32 of Example 31] NMR data of N2-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzoyl)-N5-(2-(2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)ureido)ethoxy)ethyl)-L-glutamine Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1 s. Solvent: DMSO-d6. Temperature: ~298.097 K. Scan number: 128. Frequency: 400.132470966543 MHz. Nucleus: 1H. [Figure 50][Example 33 Compound 34] LCMS, Mass Data of 1-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)urea Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 1 ml / min; Column temperature: 25° C. Eluent A: acetonitrile. Eluent B: 10 mM ammonium bicarbonate aqueous solution. Lin. Gradient: t=0 min 5% A, t=1.6 min 98% A, t=3 min 98% A. Post time: 1.3 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-320 nm). Detection: MSD ESI pos / neg (mass range 100-1000). [Figure 51] [Compound 34 of Example 33] NMR data of 1-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)urea Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1 s. Solvent: DMSO-d6. Temperature: ~297.86 K. Number of scans: 128. Frequency: 400.23247158408 MHz. Nucleus: 1H. [Figure 52][Compound 35 of Example 34] LCMS, Mass data of 1-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)urea-Cy7 adduct formate. Column: Waters XSelect CSH C18 (50×2.1 mm 3.5μ). Flow rate: 0.8 ml / min; Column temperature: 35° C. Eluent A: 0.1% formic acid in acetonitrile. Eluent B: 0.1% formic acid in water. Lin. Gradient: t=0min 5% A, t=3.5min 98% A, t=6min 98% A. Post time: 2 min. Detection: DAD (220-320 nm, 210 and 220 nm). Detection: PDA (210-800 nm). Detection: MSD ESI pos / neg (mass range: 100-1000). Detection: ELSD (Alltech 3300): Gas flow rate 1.5 ml / min, gas temperature: 40°C. [Diagram 53] [Compound 35 of Example 34] NMR data of 1-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)urea-Cy7 adduct formate salt Bruker Biospin GmbH; Pulse sequence method: zg30. Wait time: 1 s. Solvent: MeOD. Temperature: ~296.1649 K. Scan number: 64. Frequency: 400.132470966543 MHz Nucleus: 1H. [Figure 54] Overview of 1-imino-3,3,6,6-tetramethyl-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ6-thiepin 1-oxide (TMTHSI) derivatives produced according to the present invention. [Figure 55] The rate of reaction of TMTHSI with benzyl azide to determine the reaction rate constant value kt. [Figure 56]UPLC chromatograms showing A) siRNA PLK1 oligonucleotide reference, B) complete conversion of amino-modified siRNA PLK1 to TMTHSI-functionalized siRNA PLK1 oligonucleotide (Example 25, compound 26), C) complete conversion of TMTHSI-functionalized siRNA oligonucleotide upon reaction with azide-functionalized CPP1 peptide to yield CPP1-siRNA PLK1 conjugate (Example 26, compound 27), D) complete conversion of acid-labile linker NHS ester upon reaction with amine-CPP1-siRNA conjugate to yield L7-CPP1-siRNA PLK1 conjugate (Example 27, compound 28). DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0022] [Definition] The verb "comprise" as used in this specification and claims and its conjugations is used in an open-ended sense meaning that the items following the word are included, but items not specifically mentioned are not excluded. Furthermore, reference to an element by the indefinite article "a" or "an" does not exclude the possibility that there is a plurality of elements, unless the context clearly requires that only one of the elements is present. Thus, the indefinite article "a" or "an" typically means "at least one."
[0023] The compounds disclosed herein and in the claims can be described as thiocycloheptyne compounds, i.e., cycloheptyne compounds in which a combination of sulfur and a triple bond is present in the ring structure. The triple bond of the cycloheptyne moiety can be located in any of three possible positions relative to the sulfur (numbering according to "IUPAC Organic Chemistry Nomenclature", Rule 31.2). The description of any cycloheptyne compound in this specification and claims is meant to include all three individual positional isomers of the cycloheptyne moiety.
[0024] The compounds disclosed in this specification and claims may contain one or more asymmetric centers, and different diastereomers and / or enantiomers of the compound may exist. The description of any compound in this specification and claims is meant to include all diastereomers, and mixtures thereof, unless otherwise specified. Furthermore, the description of any compound in this specification and claims is meant to include both individual enantiomers, and any mixtures of racemates or other enantiomers, unless otherwise specified. When the structure of a compound is depicted as a specific enantiomer, it should be understood that the invention of this application is not limited to that specific enantiomer.
[0025] Compounds may occur in different tautomeric forms and the compounds according to the invention are meant to include all tautomeric forms unless otherwise stated.
[0026] The compounds disclosed in this specification and claims may further exist as exo and endo regioisomers. Unless otherwise specified, the description of any compound in the specification and claims is meant to include both the individual exo and individual endo regioisomers of the compound, as well as mixtures thereof.
[0027] In addition, the compounds disclosed in this specification and claims can exist as cis and trans isomers.Unless otherwise specified, the description of any compound in this specification and claims is meant to include both the individual cis and individual trans isomers of the compound, as well as their mixtures.As an example, if the structure of a compound is shown as a cis isomer, it should be understood that the corresponding trans isomer or the mixture of cis and trans isomers is not excluded from the present invention of this application.
[0028] The unsubstituted alkyl group has the general formula C n H 2n+1and may be linear or branched. Unsubstituted alkyl groups may also include cyclic moieties, and therefore may be substituted with the accompanying general formula C n H 2n-1 Optionally, the alkyl group is substituted with one or more substituents as further specified in this document. Examples of suitable alkyl groups include, but are not limited to, methyl, ethyl, propyl, 2-propyl, t-butyl, 1-hexyl, 1-dodecyl, and the like.
[0029] The unsubstituted alkenyl group has the general formula C n H 2n-1 and may be linear or branched. Examples of suitable alkenyl groups include, but are not limited to, ethenyl, propenyl, isopropenyl, butenyl, pentenyl, decenyl, octadecenyl, eicosenyl, and the like. Unsubstituted alkenyl groups also include cyclic moieties and may be represented by the accompanying general formula C n H 2n-3 may have:
[0030] The general formula for unsubstituted alkenes is C n H 2n However, the general formula for unsubstituted alkynes is C n H 2n-2 It is.
[0031] Aryl groups contain at least 6 carbon atoms and can include monocyclic, bicyclic and polycyclic structures.Aryl groups can be optionally further substituted with one or more of the substituents specified in this document.Aryl groups include, for example, phenyl, naphthyl, anthracyl and other groups.
[0032] The arylalkyl group and the alkylaryl group contain at least 7 carbon atoms and can include monocyclic and bicyclic structures. Optionally, the aryl group can be substituted with one or more substituents as further specified in this document. The arylalkyl group is, for example, benzyl, etc. The alkylaryl group is, for example, 4-t-butylphenyl, etc.
[0033] When an aryl group is indicated as a (hetero)aryl group, the designation is meant to include aryl and heteroaryl groups. Similarly, alkyl(hetero)aryl groups are meant to include alkylaryl and alkylheteroaryl groups, and (hetero)arylalkyl are meant to include arylalkyl and heteroarylalkyl groups.
[0034] Heteroaryl groups contain from one to four heteroatoms selected from the group consisting of oxygen, phosphorus, nitrogen, and sulfur.
[0035] [Compound] Starting from Almeida's thiocycloheptyne compounds, we set out to find improved compounds that could be used in copper-free click reactions. TMTH itself was found to be unsuitable for practical use due to its inherent instability (Dommerholt. Nature Communications 5, Article No: 5378 (2014)). Derivatization of the sulfur of the TMTH ring structure by direct alkylation has been reported by King et al. (Chem.Comm., 2012, 9308-9309). It has already been observed by King that the ring tension must not be pulled beyond a limit so as to prevent the reactivity of the alkyne bond, and other derivatizations are explained as not being straightforward. Furthermore, the derivatization must provide a compound suitable for reaction under aqueous conditions (high reactivity) and must withstand biological media in subsequent applications to generate suitable bioorthogonal reagents.
[0036] The inventors have surprisingly discovered that further derivatization at sulfur is possible. The resulting compounds combine high reactivity in cycloaddition reactions with good relative stability. The sulfonimines (>S(=O)(=NH)) and / or sulfonediimines (>S(=NR)2) of the present invention are a new class of compounds that can be used as bioorthogonal labels or conjugation agents. The sulfonimines and / or sulfonediimines of the present invention can be easily derivatized with other functional groups and linkers using known chemistry and further functionalized for modification, e.g., bioorthogonal labeling, imaging, or surface modification of target molecules. The compounds of the present invention can be conjugated to a wide variety of bioactive compounds and / or drug delivery systems.
[0037] TMTH and TMTH derivatives, published by King et al. (Chem.Comm., 2012, 9308-9309), were less stable and could not be used for further synthesis themselves (Li, Molecules, 2016, 21, 1393; Krebs, Tet.Lett., 1970, 761-764). However, TMTHSI compounds and derivatives according to the present invention can be synthesized and isolated, are stable to both basic and acidic purification, and can therefore be used for further synthesis. TMTHSI and TMTHSI derivatives according to the present invention have been shown to have an extended shelf life for over a year, as shown in the examples. TMTHSI and TMTHSI derivatives can be reacted with azides in acidic / neutral / basic aqueous environments and in combination with organic solvents.
[0038] Thus, in a first aspect, the present invention relates to compounds of formula (I): [ka] Where: n and m are independently 0, 1, or 2, and n+m is 2. X is O or NR 9, Y is NR 10 and R 1 , R 2 , R 3 , R 4 are independently hydrogen, halogens (F, Cl, Br, I), O, N, P and S, C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl groups, Where: O, N, P, and S can further independently be hydrogen, halogens (F, Cl, Br, I), C1-C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Attached to a cycloalkyloxy group, The alkyl group is optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; wherein the alkyl group, the (hetero)aryl group, the alkyl(hetero)aryl group and the (hetero)arylalkyl group are independently and optionally C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Substituted with one or more substituents selected from the group consisting of cycloalkyloxy groups, halogens (F, Cl, Br, I), amino groups, oxo groups and silyl groups; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted, and the alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The silyl group has the formula (R 11 )3Si-, R 11 are independent, C1~C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups and C3-C 12 cycloalkyloxy groups; The alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted, and the alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S.
[0039] R 5 , R 6 , R 7 , R 8 are independently hydrogen, halogens (F, Cl, Br, I), O, N, P and S, C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl groups, O, N, P, and S are independently hydrogen, halogens (F, Cl, Br, I), C1-C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12Alkynyl groups, C3~ C12 further attached to the cycloalkyl, the alkyl group being optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The alkyl group, the (hetero)aryl group, the alkyl(hetero)aryl group and the (hetero)arylalkyl group are independently, optionally, C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 substituted by one or more substituents independently selected from the group consisting of cycloalkyloxy, halogen (F, Cl, Br, I), amino, oxo and silyl; wherein the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted, and the alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; Here, the silyl group has the formula (R 11 )3Si-, R 11 are independent, C1~C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups and C3-C 12 cycloalkyloxy groups, wherein alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted; The alkyl, alkoxy, cycloalkyl, and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P, and S.
[0040] R 1 and R 7 , R 1 and R 8 , R 2 and R 7 , R 2 and R 8 , R 3 and R 5 , R 3 and R 6 , R 4 and R 5 , and / or R 4 and R 6 optionally independently form a fused ring system, such as cycloalkyl-, cyclo(hetero)aryl-, cycloalkyl(hetero)aryl, -cyclo(hetero)arylalkyl; The alkyl groups in the fused system are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The alkyl, (hetero)aryl, alkyl(hetero)aryl, and (hetero)arylalkyl groups of the fused system are independently any of C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl group C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Substituted with one or more groups selected from the group consisting of cycloalkyloxy groups, halogens, amino groups, oxo groups, and silyl groups; The alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted; The alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The silyl group has the formula (R 11 )3Si-, R 11 is C1~C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups and C3-C 12 cycloalkyloxy groups; The alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted, and the alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S.
[0041] R 9 , R 10 are independently hydrogen, halogen (F, Cl, Br, I), R 12 ,-CH=C(R 12 )2, -C≡CR 12 , -[C(R 12 )2C(R 12 )2O]qR 12 (q ranges from 1 to 200), -CN, -N3, -NCX, -XCN, -XR 12 , -N(R 12 )2,- + N(R 12 )3, -C(X)N(R 12 )2, -C(R 12 )2XR 12 , -C(X)R 12 , -C(X)XR 12 , -S(O)R 12 , -S(O)2R 12 , -S(O)OR12 , -S(O)2OR 12 , -S(O)N(R 12 )2, -S(O)2N(R 12 )2, -OS(O)R 12 , -OS(O)2R 12 , -OS(O)OR 12 , -OS(O)2OR 12 , -P(O)(R 12 )(OR 12 ), -P(O)(OR 12 )2, -OP(O)(OR 12 )2, -Si(R 12 )3, -XC(X)R 12 , -XC(X)XR 12 , -XC(X)N(R 12 )2, -N(R 12 )C(X)R 12 , -N(R 12 )C(X)XR 12 and -N(R 12 )C(X)N(R 12 ) 2 selected from the group consisting of X is oxygen or sulfur and R 12 are independently hydrogen, halogen (F, Cl, Br, I), C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl groups.
[0042] In a preferred embodiment, integers n and m are both 1 and the compound is of formula (II). [ka] R 1 ~R 8, X, Y are as defined elsewhere herein. Preferably, the alkyne is located at the 4-5 position relative to the sulfur (position 1). The resulting thiocycloheptyne is a symmetric compound with an axis of symmetry passing through the sulfur and alkyne bond. Compared to known BCN compounds containing both cis-trans isomerism and chiral (E / Z), the present TMTHSI compound expresses only E / Z isomerism, yet remains identical. The use of the symmetric thiocycloheptynes of the present invention as click reaction reagents avoids the generation of mixtures of isomeric compounds that may exhibit variable physicochemical or biological behavior.
[0043] In a preferred embodiment, X is O. The resulting sulfonimides have been successfully prepared with good stability and successfully derivatized as shown in the examples.
[0044] In a preferred embodiment, R 10 is H or is an alcohol, an amine, an ester, a C1-4 alkyl, a carboxylic acid, a trifluoroacetyl, and N -containing a functional group selected from the group consisting of hydroxysuccinimide (NHS) esters.
[0045] In a preferred embodiment, R 10 is H. The resulting S(=O)NH functional group is stable and has good reactivity at the NH position for further derivatization.
[0046] In a preferred embodiment, R 1 , R 2 , R 3 , R 4 are independently selected from the group consisting of H, halogen (F, CL, Br, I) and C1-C4 alkyl, preferably methyl or ethyl, or R 1 and R 2 and / or R 3 and R 4 forms a C3-C6-cycloalkyl, preferably cyclopropyl. In a further preferred embodiment, R 1 , R 2, R 3 , R 4 is independently selected from the group consisting of C1-C4 alkyl, preferably methyl or ethyl.
[0047] In a further preferred embodiment, R 1 , R 2 , R 3 , R 4 are the same and are selected from the group consisting of H, halogen and C1-C4 alkyl, or R 1 and R 2 and R 3 and R 4 forms a C3-C6-cycloalkyl, preferably cyclopropyl. In a further preferred embodiment, R 1 , R 2 , R 3 , R 4 are the same and are selected from the group consisting of H, C1-C4 alkyl, preferably methyl or ethyl (preferably methyl), or R 1 and R 2 and R 3 and R 4 forms a cyclopropyl. In a further preferred embodiment, R 1 , R 2 , R 3 , R 4 are the same and are selected from the group consisting of C1-C4 alkyl, preferably methyl or ethyl, most preferably methyl.
[0048] In one embodiment, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 are independently H, halogen (F, CL, Br, I) or C1-C 24 alkyl, preferably independently H or lower alkyl, i.e., C1-C4 alkyl, i.e., methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, or tert-butyl.1 ~R 4 are the same lower alkyl. In a more preferred embodiment, R 1 ~R 4 are all methyl.
[0049] In a preferred embodiment, R 5 , R 6 , R 7 , R 8 are independently selected from the group consisting of H, halogen (F, CL, Br, I) and C1-C4 alkyl. More preferably, R 5 , R 6 , R 7 , R 8 are the same and are selected from the group consisting of H, halogen (F, CL, Br, I) and C1-C4 alkyl, preferably methyl or ethyl. More preferably, R 5 , R 6 , R 7 , R 8 are the same and are selected from the group consisting of H and C1-C4 alkyl, preferably methyl or ethyl. 5 ~R 8 are all H.
[0050] In a particularly preferred embodiment, the compound of formula (I) is 1-imino-3,3,6,6-tetramethyl-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ of formula (III) 6 -thiepin 1-oxide. [ka]
[0051] [Synthesis] In another aspect, the present invention relates to the synthesis of the compounds of the present invention, in particular to a process for preparing a compound of formula (I), comprising the steps of: a. Conversion of the bishydrazone (2) to the iminodidehydrosulfonimino (3). b. The resulting iminodidehydrosulfonimino (3) is isolated.
[0052] The synthesis is based in part on the synthesis of TMTH by Almeida et al., using thiopanedione 1 as an intermediate in the synthesis of TMTH, which in the present invention is then converted in a single step from bishydrazone 2 to sulfonimide 3. [ka] The synthesis of diketone 1 and bishydrazone 2 has been described in detail in the literature [Almeida et al]. The synthesis begins with the conversion of diketone 1 to bishydrazone 2. The reaction is carried out in the presence of one or more hydrazines, preferably hydrazine sulfate and / or hydrazine monohydrate, preferably under pressure.
[0053] The resulting bishydrazine 2 is converted to the target compound 3 by a two-step oxidation reaction. One step of the conversion involves an oxidation reaction (addition) in which the bishydrazone (2) reacts with an oxidizing agent to oxidize the sulfur (>S) functionality to a sulfonimino (>S(=O)(=NR) functionality. The other step of the conversion is an oxidation reaction (removal) in which the bishydrazone (2) reacts with an oxidizing agent to oxidize the (bis)hydrazine (>C=NNH2)2 functionality to an alkyne (-C≡C-) functionality. In a preferred embodiment, this two-step reaction is preferably carried out in a one-step synthesis using the same oxidizing agent, preferably iodobenzene diacetate. [ka]
[0054] [Binding of linker and functional group] In a further embodiment of the invention, a linker and / or functional group is attached to the functionalized thiocycloheptyne of the invention. Thus, in a further embodiment, the invention relates to compounds in which one atom of the thiocycloheptyne ring adjacent to the X and / or Y and / or S atom of the compound of formula (I) is independently attached to an optional linking group (L) and functional group (Q) to produce a compound of formula (III). (Formula (I))-LQ (III)
[0055] The linking group (L) is absent or is a linear or branched C1-C 24 Alkylene group, C2-C 24 Alkenylene group, C2-C 24 Alkynylene group, C3-C 24 Cycloalkylene group, C5-C 24 Cycloalkenylene group, C5-C 24 Cycloalkynylene group, C7-C 24 Alkyl(hetero)arylene groups, C7-C 24 (Hetero)arylalkylene groups, C5-C 24 (Hetero)arylalkenylene group, C9-C 24 (hetero)arylalkynylene groups; The alkylene group, alkenylene group, alkynylene group, cycloalkylene group, cycloalkenylene group, cycloalkynylene group, alkyl(hetero)arylene group, (hetero)arylalkylene group, (hetero)arylalkenylene group, and (hetero)arylalkynylene group are optional and independently C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C5-C 12 Cycloalkenyl groups, C5-C 12 Cycloalkynyl groups, C8-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 is substituted with one or more substituents selected from the group consisting of cycloalkyloxy groups, halogens (F, Cl, Br, I), amino groups, oxo and silyl groups, said silyl groups being of the formula (R 11 )3Si, R 11 is defined as above.
[0056] The functional group Q is hydrogen, halogen (F, Cl, Br, I), R 12 , -CH=C(R12 )2, -C≡CR 12 , -[C(R 12 )2C(R 12 )2O] q R 12 (q ranges from 1 to 200), -CN, -N3, -NCX, -XCN, -XR 12 , -N(R 12 )2,- + N(R 12 )3, -C(X)N(R 12 )2, -C(R 12 )2XR 12 ,-C(X)R 12 ,—C(X)XR 12 ,—S(O)R 12 , -S(O)2R 12 , -S(O)OR 12 , -S(O)2OR 12 , -S(O)N(R 12 )2, -S(O)2N(R 12 )2, -OS(O)R 12 , -OS(O)2R 12 , -OS(O)OR 12 , -OS(O)2OR 12 , -P(O)(R 12 )(OR 12 ), -P(O)(OR 12 )2, -OP(O)(OR 12 )2, -Si(R 12 )3, -XC(X)R 12 , -XC(X)XR 12 , -XC(X)N(R 12 )2, -N(R 12 )C(X)R 12 , -N(R 12 )C(X)XR 12 and -N(R 12 )C(X)N(R 12 ) 2 selected from the group consisting of X is oxygen or sulfur and R 12 are independently hydrogen, halogen (F, Cl, Br, I), C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24(hetero)arylalkyl groups. Preferably, R 12 is hydrogen or C1-C6 alkyl.
[0057] If any linking group (L) and functional group (Q) are attached to one of the atoms of the thiocycloheptyne ring adjacent to the S atom, R 5 , R 6 , R 7 or R 8 is replaced with an optional linking group (L) connected to the functional group (Q). When the optional linking group (L) and the functional group (Q) are bonded to X or Y, respectively, R 9 or R 10 is substituted with an optional linking group (L) attached to a functional group (Q).
[0058] Preferably, the optional linking group (L) and functional group (Q) are attached to one of X or Y, preferably to Y, and / or to one of the atoms of the thiocycloheptyne ring adjacent to the S atom. More preferably, the optional linking group (L) and functional group (Q) are attached to one of X or Y, preferably to Y.
[0059] In one embodiment, the present invention provides compounds of formula (I), including compounds which are linked at atom X, Y, preferably at the Y atom, and / or at one atom of the thiocycloheptyne ring adjacent to the S atom, preferably at the Y atom, to an optional linking group (L) and a functional group (Q) to give a compound of formula (III). (Formula (I))-LQ (III) Here, the linking group (L) is absent or is a linear or branched C1-C 24 Alkylene group, C2-C 24 Alkenylene group, C2-C 24 Alkynylene group, C3-C 24 Cycloalkylene group, C5-C 24 Cycloalkenylene group, C5-C 24 Cycloalkynylene group, C7-C 24 Alkyl(hetero)arylene groups, C7-C 24(Hetero)arylalkylene groups, C5-C 24 (Hetero)arylalkenylene group, C9-C 24 (hetero)arylalkynylene groups; The alkylene group, the alkenylene group, the alkynylene group, the cycloalkylene group, the cycloalkenylene group, the cycloalkynylene group, the alkyl(hetero)arylene group, the (hetero)arylalkylene group, the (hetero)arylalkenylene group and the (hetero)arylalkynylene group are optionally C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C5-C 12 Cycloalkenyl groups, C5-C 12 Cycloalkynyl groups, C8-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 and substituted with one or more substituents independently selected from the group consisting of cycloalkyloxy groups, halogens (F, Cl, Br, I), amino groups, oxo, and silyl groups, the silyl groups being represented by the formula (R 11 )3Si, R 11 is defined as above.
[0060] where the functional group Q is hydrogen, halogen (F, Cl, Br, I), R 12 , -CH=C(R 12 )2, -C≡CR 12 , -[C(R 12 )2C(R 12 )2O] q R 12 (q ranges from 1 to 200), -CN, -N3, -NCX, -XCN, -XR 12 , -N(R 12 )2,- + N(R 12 )3, -C(X)N(R 12 )2, -C(R 12 )2XR 12 ,-C(X)R 12 ,—C(X)XR 12,—S(O)R 12 , -S(O)2R 12 , -S(O)OR 12 , -S(O)2OR 12 , -S(O)N(R 12 )2, -S(O)2N(R 12 )2, -OS(O)R 12 , -OS(O)2R 12 , -OS(O)OR 12 , -OS(O)2OR12, -P(O)(R 12 )(OR 12 ), -P(O)(OR 12 )2, -OP(O)(OR 12 )2, -Si(R 12 )3, -XC(X)R 12 , -XC(X)XR 12 , -XC(X)N(R 12 )2, -N(R 12 )C(X)R 12 , -N(R 12 )C(X)XR 12 and -N(R 12 )C(X)N(R 12 ) 2, X is oxygen or sulfur, and R 12 are independently hydrogen, halogen (F, Cl, Br, I), C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl groups.
[0061] A wide variety of linkers can be used, and the selection of the linker can be based on, for example, other criteria related to the end use, essentially as disclosed elsewhere herein.
[0062] In a preferred embodiment, L is absent or is [C(R 12 )2C(R 12 )2O]qR 12 (q ranges from 1 to 200), -CN, -NCX, -XCN, XR 12 , -N(R 12)2,- + N(R 12 )3, -C(X)N(R 12 )2, -C(R 12 )2XR 12 , -C(X)R 12 , -C(X)XR 12 , -S(O)R 12 , S(O)2R 12 , -S(O)OR 12 , -S(O)2OR 12 , -S(O)N(R 12 )2, -S(O)2N(R 12 )2, -OS(O)R 12 , -OS(O)2R 12 , -OS(O)OR 12 , -OS(O)2OR 12 , -P(O)(R 12 )(OR 12 ), -P(O)(OR 12 )2, -OP(O)(OR 12 )2, -Si(R 12 )3, XC(X)R 12 , -XC(X)XR 12 , -XC(X)N(R 12 )2, -N(R 12 )C(X)R 12 , -N(R 12 )C(X)XR 12 and N(R 12 )C(X)N(R 12 )2, X is oxygen or sulfur, and R 12 is as defined elsewhere.
[0063] In further preferred embodiments, L is absent or is a chain having a length of 1 to 25 atoms, preferably 1 to 15 atoms, and preferably comprises one or more, preferably 1 to 6, moieties independently selected from the group consisting of -S(O)2-, -S-, -SS-, C(O)NH-, -NHC(O)-, -C(O)O- and phenylene, whereby the length of said chain is determined by the number of atoms in the longest linear chain of atoms. Said longest linear chain may further comprise one or more heteroatoms such as O, N, S and P. Preferably, it further comprises one or more O atoms. In preferred embodiments, L comprises 1, 2, 3, 4 or 5 moieties independently selected from the group consisting of -S(O)2-, -S-, -SS-, -C(O)NH-, -NHC(O)-, -C(O)O- and phenylene. Furthermore, said chain, having a length of 1 to 25 atoms, preferably 1 to 15 atoms, is unbranched, i.e. the chain is linear, optionally with the exception of the heteroatom(s) in the -S(O)2-, -C(O)NH-, -NHC(O)-, C(O)O- moiety(s) which are not included in the linear chain.
[0064] In one embodiment, Q is -OR 12 , -N(R 12 )2,- + N(R 12 )3, -C(O)N(R 12 )2, -C(O)OR 12 , -OC(O)R 12 , -OC(O)OR 12 , -OC(O)N(R 12 )2, -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 and -N(R 12 )C(O)N(R 12 )2, wherein R 12 is as defined elsewhere herein.
[0065] In preferred embodiments, Q includes an alcohol, an amine, a thiol, a carboxylate, a carboxylic acid or activated ester, a ketone, an aldehyde, a nitrile, a maleimide, an alkene, an alkyne, a heteroaromate, a leaving group, and a phosphoramidite. In particularly preferred embodiments, Q is an alcohol, an amine, a carboxylate, a carboxylic acid, or an N-hydroxysuccinimide (NHS) ester.
[0066] In one embodiment, the coupling of the linker L and / or functional group Q is to the functionalized sulfur of the thiocycloheptyne, i.e., to X and / or Y of the S(=X)(=Y) portion of the molecule. The coupling is to a functional group, optionally via a linker. The functional group Q links to any molecule of interest.
[0067] In certain embodiments, Q is linked to one or more of a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle, a carrier, or a combination thereof. Such coupling chemistries are well developed and one of skill in the art can select an appropriate coupling chemistry to attach Q to a molecule of interest.
[0068] [Click reaction] The alkyne group of the compound of the present invention is reactive and can be functionalized, for example, using a cycloaddition type reaction. In an embodiment, the alkyne group can be reacted with a compound containing a 1,3-dipole or a 1,3-(hetero)dienes. In a particular embodiment, the compound containing a 1,3-dipole or a 1,3-(hetero)dienes is an azide-containing compound, a nitrone-containing compound, or a nitrile oxide-containing compound. Most preferred is an azide-containing compound. In an embodiment, the azide-containing compound can be coupled using a copper-free click reaction. The coupling results in a triazole-type structure.
[0069] The compounds of the present invention are dual-functional compounds with reactive sites at functionalized sulfur positions and alkyne functional groups. Both functionalizations can be independently, one via any linker (L) and functional group (Q), the other via click chemistry. The functionalizations can be independently conjugation with drugs (small molecules, genetic materials, etc.), antibodies, proteins, peptides, ligands, imaging labels, targeting ligands, delivery agents, nanoparticles, carriers.
[0070] Thus, in one embodiment, the functional group Q is attached, optionally via a linker L, to one or more of a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle, a carrier.
[0071] In another embodiment, the alkyne can be attached to one or more of a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle, a carrier. The coupling of the alkyne is preferably carried out via reaction of the alkyne with a compound containing a 1,3-dipole or a 1,3-(hetero)diene. In a particular embodiment, the compound containing a 1,3-dipole or a 1,3-(hetero)diene is an azide-containing compound, a nitrone-containing compound, or a nitrile oxide-containing compound, more preferably an azide-containing compound.
[0072] The compounds of the invention are therefore suitable for creating combinations of two molecules / functional groups of interest via 1,3 dipoles / 1,3-(hetero)dienes / thiacycloheptyne derivatives / (linkers) / functional groups. Schematically, this general principle of application of the thiacycloheptynes of the invention is illustrated in the table below.
[0073] [Table 1]
[0074] The linkers used may be biodegradable, ie, initially stable, but may become cleavable over time or under certain circumstances, such as physiological conditions.
[0075] In certain embodiments, the combination is preferred in which the nanoparticle is coupled via any linker / 1,3-dipole or 1,3-heterodiene / thiocycloheptyne / any linker to a functional group / molecule of interest selected from drugs, antibodies, proteins, peptides, ligands, imaging labels, targeting ligands, delivery agents, nanoparticles, and carriers. The nanoparticle itself may comprise a drug, antibody, protein, or peptide. The preferred 1,3-dipole or 1,3-heterodiene for coupling nanoparticles to the thiocycloheptyne derivatives of the invention is azide (N3).
[0076] [Nanoparticles] Drug delivery systems are increasingly being used in pharmaceutical science. Through an elaborate series of derivatizations, drugs can be delivered, targeted, monitored and delivered to patients with enhanced efficacy and effectiveness. The use of these drug delivery systems, such as nanoparticles, proteins, hydrogels, liposomes, antibody drug conjugates and drug polymer conjugates, is rapidly developing in pharmaceutical science.
[0077] Pharmaceutical scientists are using these systems to reduce drug toxicity and side effects, improve delivery, and add imaging ligands to aid in efficacy monitoring.
[0078] Nanoparticles, usually with a diameter <100 nm, have been produced from a variety of materials and are expected to have applications in medicine, such as both in vitro and in vivo diagnostics, nutraceuticals, and the production of improved biocompatible materials. Nanoparticles can be customized for specific purposes and are available in a variety of materials. Most pharma- ceutical interesting nanoparticles are based on (bio)polymeric materials that can be of various forms. The raw materials can be of biological origin, such as phospholipids, lipids, lactate, dextran, chitosan, or they can have more "chemical" properties, such as various (co)polymers. These nanoparticles are usually functionalized by connecting, coupling, or (covalently) attaching active components (drugs, ligands, imaging ligands, etc.). The functionalization of many of these nanoparticles can be achieved by various wired chemistries, such as copper-free click chemistry using the thiocycloheptyne derivatives of the present invention.
[0079] In certain embodiments, the nanoparticles are preferably self-assembled polymeric micelles from thermosensitive block copolymers. In particular, copolymers based on PEG-b-poly(N-hydroxyalkylmethacrylamide-oligolactate) with partially methacrylated oligolactate units are preferred, but other (meth)acrylamide esters can also be used to construct the thermosensitive block, such as esters of HPMAm (hydroxypropylmethacrylamide) and HEMAm (hydroxyethylmethacrylamide) and optionally (oligo)lactate esters and N(meth)acryloylamino acid esters. Also, preferred thermosensitive block copolymers are derived from monomers containing functional groups that can be modified, i.e., modified by derivatized and non-derivatized methacrylate groups, such as HPMAm-lactate polymers, including the incorporation of linker moieties.
[0080] Other types of functional thermosensitive (co)polymers that can be used include hydrophobically modified poly(N-hydroxyalkyl)(meth)acrylamides, copolymer compositions of N-isopropylacrylamide (NIPAAm) with other moieties such as monomers containing reactive functional groups (e.g., acid acrylamide and N-acryloxysuccinimide), or similar copolymers such as poly(alkyl)2-oxazalines. Further preferred thermosensitive groups can be based on NIPAAm and / or alkyl-2-oxazalines, which monomers can react with monomers containing reactive functional groups such as (meth)acrylamides or (meth)acrylates containing hydroxyl, carboxyl, amine or succinimide groups.
[0081] Suitable thermosensitive polymers are described in US Pat. No. 7,425,581 and EP-A-1 776 400. Further, they are described in WO 2010 / 033022 and WO 2013 / 002636.
[0082] WO 2012 / 039602 describes drug-polymer matrix particles using such polymers, and WO 2012 / 039602 further describes biodegradable linker molecules that can be used with these known polymer matrix particles.
[0083] In general, nanoparticles based on thermosensitive block copolymers as outlined above can be coupled to the compounds of the invention using azide-alkyne copper-free coupling, examples of which are described in WO 2017 / 086794.
[0084] Thus, in certain embodiments of the present invention, nanoparticles are prepared in which the thiocycloheptyne derivatives of the present invention are attached to azide-containing nanoparticles, hi certain embodiments, the nanoparticles are self-assembled polymeric micelles, preferably from thermosensitive block copolymers.
[0085] The present invention optionally relates to the use of the thiocycloheptyne derivatives of the present invention in a coupling method for coupling two molecules of interest, independently selected from drugs, antibodies, proteins, peptides, ligands, imaging labels, targeting ligands, delivery agents, nanoparticles and carriers. The present invention further relates to the use of the thiocycloheptyne derivatives of the present invention in a bioorthogonal reaction, optionally a copper-free click reaction, and the use of the method of coupling nanoparticles using a copper-free click reaction with one or more of drugs, antibodies, proteins, peptides, ligands, imaging labels, targeting ligands, delivery agents, nanoparticles and carriers. The coupling of the compounds of the present invention with azide-containing thermosensitive polymers is advantageous because click chemistry between the alkyne-containing compounds of the present invention and azides is faster compared to conventional alkynes used in click chemistry, especially in the preparation of biodegradable nanoparticles and complexed / encapsulated drugs.
[0086] Features of the invention are described herein as part of the same or separate aspects or embodiments for purposes of clarity and concise description. It will be understood by those skilled in the art that the scope of the invention may include embodiments having all or some combination of the features described herein as part of the same or separate embodiments.
[0087] The invention will now be described in more detail by the following non-limiting examples.
[0088] [Example] FIG. 54 shows the 1-imino-3,3,6,6-tetramethyl-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ of the present invention. 6 1 shows an overview of TMTHSI derivatives, the synthesis of which is described in the Examples below.
[0089] The TMTHSI core structure (Example 2) can be functionalized in a variety of ways.
[0090] Example 2, X=O, Y=N, core TMTHSI structure, R 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0091] Example 3, X=O, Y=N, adds to Example 2 L=succinic linker, Q=activated NHS ester. 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0092] Example 5 replaces the NHS ester of Example 3 by reaction with benzylamine. 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0093] Example 8 (X=O, Y=N) replaces the NHS ester of Example 3 by reaction with the HER2 peptide. 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0094] Example 11 (X=O, Y=N) replaces the NHS ester of Example 3 by reaction with a diamino PEG spacer (=L). Q is an amine. R 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0095] Example 12 (X=O, Y=N) [ka] R 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0096] Example 13 (X=O, Y=N-trifluoroacetamide, L=no linker, Q=no functionality).1 ~R 4 = methyl, R 5 ~R 8 = hydrogen. This compound is intended for α-sulfur substitution.
[0097] Example 14 (X=O, Y=N) replaces the NHS ester of Example 12 by reaction with an amino-PEG-hydroxyl spacer (=L). Q is hydroxyl, R 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0098] Example 15 (X=O, Y=N) is the compound of Example 2, with L=-S(O2)phenyl and Q=3-methoxycarbonyl. 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0099] Example 16 (X=O, Y=N) is the compound of Example 2 to which L=-S(O2)phenyl and Q=3-hydroxycarbonyl are bonded. R1 to R4=methyl, R5 to R8=hydrogen
[0100] Example 17 (X=O, Y=N-methyl), L=no linker. Q=no functionality. 1 ~R 4 = methyl, R 5 ~R 8 = hydrogen. This compound is intended for α-sulfur substitution.
[0101] Example 18 (X=O, Y=N-methyl), L=no linker. Q=no functionality. 1 ~R 4 = methyl, R 5 ~R 8 = one hydrogen is replaced with L = methylenephenyl, Q = 4-methoxycarbonyl. This compound is an α-sulfur substituted variant of TMTHSI.
[0102] Example 19 (X=O, Y=N) is the compound of Example 2 with L=methylenephenyl and Q=4-methoxycarbonyl.1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0103] Example 23 (X=O, Y=N) is the same as Example 12 except that the NHS moiety is replaced by a cystamine-based amine linker. L=-C(O)NHC2H4SSC2H4NHC(O)C3H6, Q=COOH. [ka] R 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0104] Example 24 (X=O, Y=N) is the NHS ester activated version of Example 23. L=-C(O)NHC2H4SSC2H4NHC(O)C3H6-, Q=((2,5-dioxopyrrolidin-1-yl)oxy)carbonyl, C(O)OSu. [ka] R 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0105] Example 25 (X=O, Y=N) replaces the NHS ester of Example 24 by reacting with an amino-C6 functionalized siRNA oligonucleotide. 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0106] Example 31 (X=O, Y=N) replaces the NHS ester of Example 12 by reacting with an amino PEG-functionalized folic acid. 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0107] Example 33 (X=O, Y=N) replaces the NHS ester of Example 12 by reaction with a diamino PEG spacer (=L). Q is an amine. R 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0108] Example 34 (X=O, Y=N) reacts Example 33 with a Cy7NHS label. L=diaminoPEG spacer, R 1 ~R 4 = methyl, R 5 ~R 8 = Hydrogen
[0109] In addition to the configurations prepared in the following examples and / or shown in FIG. 1 ~R 8 One skilled in the art can provide further derivatives having further variables for L and / or Q, and coupling to further molecules of interest such as drugs, antibodies, proteins, peptides, ligands, imaging labels, targeting ligands, delivery agents, nanoparticles or carriers using reactions known in the art.
[0110] [Example 1: Synthesis of (3,3,6,6-tetramethylthiepane-4,5-diylidene)bis(hydrazine)] [ka] A glass autoclave (300 mL) was charged with 3,3,6,6-tetramethylthiepane-4,5-dione (6.17 g, 30.8 mmol), ethanol (2.4 mL), and ethylene glycol (60 mL). To the stirred mixture was added hydrazine sulfate (16.03 g, 123 mmol, 4 equiv.) and hydrazine monohydrate (3 mL, 61.6 mmol, 2 equiv.). The autoclave was closed and heated in an oil bath at 140 °C for 20 h.
[0111] After cooling to room temperature, the mixture was partitioned between water (500 ml) and diethyl ether (200 ml) and transferred to a separatory funnel, filtering through a cotton pad to remove some white solid residue (presumably hydrazine sulfate, as the residue dissolves slowly in water). The phases were separated and the aqueous phase was extracted with diethyl ether (2×100 ml). The combined ether phases were washed with water (2×75 ml) and brine (100 ml), dried over Na2SO4, and concentrated under reduced pressure to give 5.75 g of crude product as a thick yellow oil.
[0112] The residue was purified by flash column chromatography (40 g silica; 30% EtOAc in heptane). The product fractions were combined and concentrated under reduced pressure. The residue was co-evaporated with diethyl ether to give 0.9 g (12%) of the product as an off-white solid. GC / MS (Method A)t R 4.47min, M+=228. * 1 H NMR (400 MHz, chloroform-d) δ 5.24 (s, 4H), 2.54 (d, J = 14.4 Hz, 2H), 2.48 (d, J = 14.4 Hz, 2H), 1.34 (s, 6H), 1.21 (s, 6H).
[0113] [Example 2: 1-Imino-3,3,6,6-tetramethyl-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ 6 -Synthesis of thiepin 1-oxide (TMTHSI) [ka] In an 8 ml screw cap vial, (3,3,6,6-tetramethylthiepane-4,5-diylidene)bis(hydrazine) (100 mg, 0.44 mmol) and ammonium acetate (270 mg, 3.5 mmol, 8 equiv) were suspended in methanol (0.4 ml). The mixture was cooled with ice / water. A solution of iodobenzene diacetate (494 mg, 1.53 mmol, 3.5 equiv) in a mixture of MeOH (0.4 ml) and dichloromethane (0.6 ml) was added dropwise to control the exotherm and gas formation (the reaction showed gas evolution with each drop added). After the addition was complete, the mixture was stirred at room temperature for 1 h.
[0114] The mixture was diluted with dichloromethane (2 ml) and quenched with brine (1 ml). The organic layer was removed by pipette and passed through a phase separator. Each time the organic phase was passed through a phase separator and combined with the previous extract, the aqueous residue was extracted with dichloromethane (×2). The organic extracts were concentrated under reduced pressure, carefully monitoring evaporation as the product may be volatile, to give 427 mg of crude product as a yellow oil. The residue was purified by preparative RP-MPLC (Reveleris, XSelect; 10–50% aqueous MeCN, 10 mM NH4HCO3, pH=9.5). The product fractions were combined and extracted with dichloromethane (3×), and each organic extract was passed through a phase separator and concentrated under reduced pressure. The residue was coevaporated with heptane and diethyl ether to give 33 mg (37%) of a crystalline residue. LC / MS(SC BASE)t R 1.628min, purity 98.1%, mass detection [M+H] + 200. 1 H NMR (400 MHz, chloroform-d) δ 3.26 (d, J = 14.1 Hz, 2H), 3.18 (d, J = 14.1 Hz, 2H), 2.76 (s, 1H), 1.46 (s6H), 1.30 (s, 6H).
[0115] TMTHSI proved to be stable during storage. Compound 3 was stored as a powder under atmospheric pressure in both light and darkness. 1H-NMR en LC / MS (SC BASE) demonstrated that the compound did not degrade after 10 months of storage.
[0116] [Example 3: Coupling to a linker 2,5-dioxopyrrolidin-1-yl 4-oxo-4-((3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 Synthesis of -thiepin-1-ylidene)amino)butanoate [ka] Diisopropylethylamine (266 μl, 1.52 mmol, 2 equiv.) was dissolved in 1-imino-3,3,6,6-tetramethyl-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ in dichloromethane (5 ml). 6 -Thiepine 1-oxide (152 mg, 0.76 mmol) and succinic anhydride (114 mg, 1.14 mmol, 1.5 equiv.) was added and the resulting mixture was stirred at room temperature for 20 h.
[0117] The reaction mixture was concentrated under reduced pressure, redissolved in dichloromethane, and concentrated under reduced pressure again. The residue was redissolved in dichloromethane (5 ml) and N-hydroxysuccinimide (220 mg, 1.91 mmol, 2.5 equiv) was added. The mixture was stirred for 5 min, then a suspension of N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride (366 mg, 1.91 mmol, 2.5 equiv) in dichloromethane (0.5 ml) was added via pipette. The resulting solution was stirred at room temperature for 4 h.
[0118] The mixture was quenched with 2M aqueous KHSO4 and the organic phase was passed through a phase separator. The filtrate was concentrated under reduced pressure to give 420 mg of the crude mixture as a foam.
[0119] The residue was purified by flash column chromatography (12 g silica, 50-75% EtOAc in heptane) and the product fractions were pooled and concentrated under reduced pressure to give 141 mg (46%) of the product as a white solid. LC / MS(SC_ACID)tR 1.84min, purity 85%, mass detection [M+H] + 397. 1 H NMR (400 MHz, chloroform-d) δ 3.79 (d, J = 14.1 Hz, 2H), 3.63 (d, J = 14.2 Hz, 2H), 2.97-2.90 (m, 2H), 2.88-2.81 (m, 4H), 2.79-2.71 (m, 2H), 1.55 (s, 6H), 1.28 (s, 6H).
[0120] [Example 4: Binding to a linker. 1 -Benzyl-N 4 -(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 Synthesis of Thiepin-1-ylidene Succinamide [ka] 2,5-Dioxopyrrolidin-1-yl 4-oxo-4-((3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 To a solution of 1-thiepin-1-ylidene)amino)butanoate (15.8 mg, 0.040 mmol) in dichloromethane (1 ml) was added benzylamine (8.71 μl, 0.080 mmol, 2 equiv). The reaction mixture was stirred at room temperature for 4 h. The reaction mixture was then purified by flash column chromatography (silica, 12 g; 70-100% EtOAc in heptane) and the product fractions were combined and concentrated under reduced pressure to give 13.1 mg of product with a purity of approximately 83% by LC / MS.
[0121] The material was purified by preparative RP-MPLC (Reveleris, XSelect; 20-60% MeCN in water, 10 mM NH4HCO3, pH=9.5) and the product fractions were pooled and concentrated under reduced pressure to give 6.2 mg (40%) of the title compound as a white solid. LC / MS(SC BASE)t R2.01min, purity 96.8%, mass found [M+H] + 389. 1 H NMR (400MHz, chloroform-d) δ7.36-7.22(m,5H),6.25(s,1H),4.44(d,J=5.7Hz,2H)3.60(d,J=14.1Hz,2H),3. 53(d,J=14.1Hz,2H),2.73(dd,J=6.8,6.2Hz,2H),2.52(dd,J=6.6,6.4Hz,2H),1.49(s,6H),1.24(s,6H).
[0122] [Example 5: Click reaction 1-benzyl-6-imino-4,4,8,8-tetramethyl-1,4,5,6,7,8-hexahydro-6λ 4 -Synthesis of thiepino[4,5-d][1,2,3]triazole 6-oxide] [ka] LC / MS: 1-Imino-3,3,6,6-tetramethyl-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ 6 -thiepine 1-oxide (5 mg, 0.025 mmol) was loaded into an LC / MS vial, then dissolved in MeCN (1 ml), benzyl azide was added, and the reaction mixture was analyzed by LC / MS, which showed complete disappearance of the starting material and formation of the product as a mixture with unreacted benzyl azide. LC / MS(SC BASE)t R 1.728min, purity 64%, mass found [M+H] + 333.
[0123] 1 H-NMR: 1-Imino-3,3,6,6-tetramethyl-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ 6 Thiepin 1-oxide (5 mg, 0.025 mmol) was dissolved in CDCl3 (0.6 ml) and then benzyl azide was added. 11 H-NMR was recorded after about 15 min of reaction time. 1 H NMR (400MHz, chloroform-d) δ7.40-7.29(m,3H),7.06-7.01(m,2H),5.73(s,2H),3. 45(d,J=8.9Hz,4H),2.69(s,1H),1.70(d,J=2.1Hz,6H),1.44(d,J=2.7Hz,6H).
[0124] Total consumption of starting material, with .about.35 mol % excess of benzyl azide present.
[0125] [Example 6: Click Reaction N 1 -Benzyl-N 4 -(1-benzyl-4,4,8,8-tetramethyl-6-oxide-4,5,7,8-tetrahydro-1H-6λ 4 Synthesis of -thiepino[4,5d][1,2,3]triazol-6-ylidene)succinamide [ka] N dissolved in CDCl 1 -Benzyl-N 4 -(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 To an NMR tube containing 4.6 mg (12 μmol) of (-thiepin-1-ylidene)succinamide was added a solution of benzyl azide in CDCl3 (10 vol%, 15.5 μl, 1.05 equiv.). The mixture was shaken and after a reaction time of about 5 min, 1 H-NMR analysis was carried out. 1H NMR (400MHz, chloroform-d) δ7.43-7.27(m,8H),7.06-7.00(m,2H),6.18(s,1H) ,5.72(s,2H),4.42(d,J=5.8Hz,2H),3.96(d,J=15.5Hz,1H),3.82(d,J=15. 0Hz,1H),3.70(d,J=15.3Hz,1H),3.57(d,J=15.1Hz,1H),2.74-2.67(m,2H) ,2.49(t,J=6.7Hz,2H)1.70(s,3H),1.67(s,3H),1.44(s,3H),1.36(s,3H).
[0126] The mixture was concentrated to dryness and the residue was analyzed by LC / MS.
[0127] LC / MS (SC_BASE) is a method to measure the target mass (t R 1.947min, purity 75%, [M+H] + 522) showed a product peak.
[0128] LC / MS (SC_ACID) is a method to detect the target mass ([M+H] + 522) and two product peaks [resp.t R 1.90 (57%) and 1.94 min (23%).
[0129] Example 7: Coupling of TMTHSI-containing linkers to HER2-peptides Preparation of TMTHSI-succinyl-Fcycl[CGDGFYAC]YMDV [ka] Fcycl[CGDGFYAC]YMDV (20 mg, 13 μmol) was placed in an 8 ml screw-cap vial and dissolved in DMSO (1 ml). 2,5-dioxopyrrolidin-1-yl 4-oxo-4-((3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6-Thiepin-1-ylidene)amino)butanoate (6.5 mg, 14 μmol, 1.04 equiv.) was added, followed by diisopropylethylamine (13 μl, 75 μmol, 5.6 equiv.). The mixture was stirred at room temperature for 16 h. The reaction mixture was directly purified by preparative RP-MPLC (Reveleris), LUNA-C18, 20-60% MeCN in water, 0.1% formic acid) and the product fractions were pooled and lyophilized to give 16.6 mg (69%) of product. LC / MS(AN BASE M1800) R 2.57min, purity 96%, mass found [MH] - 1768, [M-2H] 2- 883.
[0130] [Analysis method] [GC / MS analysis method] [Method A] Instrument: GC: Agilent 6890N, FID: Detector temperature: 300°C, and MS: 5973 MSD, EI-positive, Detector temperature: 280°C, Mass range: 50-550; Column: RXi5-MS 20m, ID 180μm, df 0.18μm; Average velocity: 50cm / s; Injection volume: 1μl; Injector temperature: 250°C; Split ratio: 20 / 1; Carrier gas: He; Initial temp: 100°C; Initial time: 1.5min; Solvent delay: 1.3min; Heat rate: 75°C / min; Final temp: 250°C; Final time: 2.5min.
[0131] [LC / MS measurement method] [SC_ACID] Instrument: Agilent 1260 binary pump: G1312B, degasser; autosampler, ColCom; DAD: Agilent G1315D, 220-320 nm; MSD: Agilent LC / MSD G6130B ESI, pos / neg 100-1000, ELSD Alltech 3300 gas flow 1.5 ml / min, gas temperature: 40°C; Column: Waters XSelect™ C18, 30 x 2.1 mm, 3.5 μ, temperature: 35°C, flow rate: 1 mL / min, gradient: t0 = 5% A, t 1.6min =98% A,t 3min =98% A, post time: 1.3 min, eluent A: 0.1% formic acid in acetonitrile, eluent B: 0.1% formic acid in water.
[0132] [SC BASE] Instrument: Agilent 1260 Binary pump: G1312B, degasser; autosampler, Colcom; DAD: Agilent G1315C, 220-320 nm; MSD: Agilent LC / MSD G6130B ESI, pos / neg 100-1000; Column: Waters XSelect™ CSH C18, 30×2.1 mm, 3.5 μ, Temperature: 25°C, Flow rate: 1 mL / min, Gradient: t0=5% A, t 1.6min =98% A,t 3min =98% A, post time 1.3 min, eluent A: acetonitrile, eluent B: 10 mM ammonium bicarbonate aqueous solution (pH = 9.5).
[0133] [AN BASE_M1800] Equipment: Agilent 1260 binary pump: G1312B, degasser; autosampler, ColCom; DAD: Agilent G1315C, 220-320 nm; MSD: Agilent LC / MSD G6130B ESI, pos / neg 800-1800; Column: Waters XSelect™ CSH C18, 50×2.1 mm, 3.5 μ, temperature: 25° C., flow rate: 0.8 mL / min, gradient: t0=5% A, t 3.5min =98% A,t6min =98% A, post time: 2 min, eluent A: acetonitrile, eluent B: 10 mM ammonium bicarbonate aqueous solution (pH = 9.5).
[0134] [ 1 H-NMR] All 1 H-NMR spectra were recorded on a Bruker Avance-400 Ultrashield NMR spectrometer using CDCl3 or DMSO-d6 as solvents and are reported in ppm using TMS (0.00 ppm) as the internal standard.
[0135] Example 8: Coupling of TMTHSI-containing linker HER2-peptide to azide-containing nanoparticles (CriPec) [ka] Core-crosslinked polymeric micelles labeled with HER2 peptides were generated by conjugating HER2 peptides to the surface of the polymeric micelle shell and used for targeting studies. To enable HER2 peptide conjugation by click chemistry, azide-functionalized polymeric micelles were essentially fabricated according to a reported protocol [Hu et al. Biomaterials.2015;53:370-8]. However, a portion of the azide-functionalized block copolymer (7.5 kDa, derivatized with 10 mol% crosslinker L2 [1], 5 w% of the total block copolymer) was added next to a (95 w%) non-functionalized block copolymer (7.5 kDa, derivatized with 10 mol% crosslinker L2 [Biomaterials.2015;53:370-8], 95 w% of the total block copolymer). These two block copolymers were then combined with azide-PEG 5000 The former was synthesized from -OH (azide-PEG 5000) were synthesized following the same procedure, except that 2-ABCPA initiator was used instead. The resulting azide-functionalized polymeric micelles were then purified in 20 mM ammonium acetate pH 5 buffer containing 130 mM NaCl, buffer exchanged into 20 mM sodium phosphate pH 7.4 buffer containing 130 mM NaCl, and concentrated to approximately 30 mg / mL polymer equivalents using tangential flow filtration (TFF) with a modified polyethersulfone (mPES) 100 kDa module (Spectrumlabs). HER2 peptide was then conjugated to the concentrated azide-functionalized core-crosslinked polymeric micelles via copper-free click chemistry using the following procedure.
[0136] At room temperature (RT), ACN (86 μL) was added to 200 μL of azide-functionalized modified core-crosslinked polymeric micelles (0.4 μmol azide equivalent) in an amber UPLC vial with stirring (300 rpm). After cooling, HER2 peptide (1.0 equiv., 0.4 μmol, 86 μL, Merachem) was added dropwise to the reaction mixture. The progress of the conjugation reaction was monitored by UPLC-UV for 24 h, after which the reaction was stopped. Based on UPLC, the conversion rate of HER2 peptide was determined to be 43%. This corresponds to 2.2% of the core-crosslinked polymeric micelles labeled with HER2 peptide. After the conjugation reaction, the HER2 peptide-labeled polymeric micelles were purified by TFF against 10 v% ethanol to remove unreacted HER2 peptide.
[0137] Example 9: Coupling of TMTHSI-containing linker HER2-peptide to azide-containing nanoparticles (CriPec) at acidic pH To enable HER2 peptide conjugation by click chemistry, azide-functionalized polymeric micelles were prepared essentially according to a reported protocol [Hu et al. Biomaterials 2015;53:370-8], except that a portion of the azide-functionalized block copolymer (7.5 kDa, 5 w% of the total block copolymer amount was derivatized with 10 mol% crosslinker L2 [1]) was added next to a (95 w%) non-functionalized block copolymer (7.5 kDa, 95 w% of the total block copolymer amount was derivatized with 10 mol% crosslinker L2 [Biomaterials.2015;53:370-8)]. These two block copolymers were then mixed with azide-PEG 5000 The former was synthesized from -OH (azide-PEG 5000 ) was synthesized according to the same procedure, except that 2-ABCPA initiator was used instead. The resulting azide-functionalized polymeric micelles were then purified with 20 mM ammonium acetate pH 5 buffer containing 130 mM NaCl and concentrated to approximately 60 mg / mL polymer equivalents using tangential flow filtration (TFF) with a modified polyethersulfone (mPES) 100 kDa module (spectrumlabs). HER2 peptide was then conjugated to the concentrated azide-functionalized core-crosslinked polymeric micelles via copper-free click chemistry using the following procedure.
[0138] 150 mM ammonium acetate (130 μL) at pH 5 at room temperature (RT) was added to 1500 μL of azide-functionalized modified core-crosslinked polymeric micelles (0.57 μmol azide equivalents) in an amber UPLC vial with stirring (300 rpm). After cooling, HER2 peptide (5.0 equiv., 2.85 μmol, 842 μL 2 mg / ml HER2-TMTH stock solution) was added dropwise to the reaction mixture. The progress of the conjugation reaction was monitored by UPLC-UV for 24 h, after which the reaction was stopped. Based on UPLC, the conversion rate of HER2 peptide was determined to be 23%. This corresponds to core-crosslinked polymeric micelles labeled with 5% HER2 peptide. After the conjugation reaction, the HER2 peptide-labeled polymeric micelles were purified by TFF against 10 v% ethanol to remove unreacted HER2 peptide.
[0139] [Example 10: Comparison of reaction rates of model click reactions between TMTHSI and BCNOH and benzyl azide] The alkyne (TMTSHI or BCN-OH) was reacted with 1.3 equivalents of benzyl azide and the reaction rate was measured using NMR (CDCl3). The conversion of TMTHSI with benzyl azide reached 79% after 225 seconds, while the reaction with BCN-OH took about 40 times longer (9312 seconds). The reaction conversion (%) was calculated based on the triazole signal, taking the plateau of the triazole signal at the end of the reaction as the 100% level = when all TMTHSI or BCN-OH had completely reacted with benzyl azide. The measurement results are included in Figure 17A. TMTHSI (upper curve) is significantly faster than BCN-PH (lower curve). A zoomed-in version of the TMTHSI measurement is shown in Figure 17B.
[0140] [Example 11: N 1 -(2-(2-(2-aminoethoxy)ethoxy)ethyl)-N 4 (3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 Synthesis of (thiepan-1-ylidene)succinamide [ka] 2,5-Dioxopyrrolidin-1-yl 4-oxo-4-((3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 A solution of 1,2-bis(2-aminoethoxy)ethane (131 μl, 0.90 mmol, 4 equiv.) in dichloromethane (5 ml) was added dropwise over 5 min to a solution of 1,2-bis(2-aminoethoxy)ethane (131 μl, 0.90 mmol, 4 equiv.) in dichloromethane (5 ml). After the addition was complete, the mixture was stirred at room temperature for 15 min. The mixture was then quenched with saturated aqueous NH4Cl (5 ml) and the organic phase was pipetted into a phase separator. Each time the organic phase was pipetted into a phase separator, the aqueous residue was extracted (2×) with dichloromethane. The combined filtrates were concentrated under reduced pressure to give 47.7 mg of crude product. The residue was purified by preparative RP-MPLC (Liberalis, XSelect 10-50% MeCN in water, 10 mM NH4HCO3, pH = 9.5) and the product fractions were combined and concentrated under reduced pressure to approximately 15 ml, transferred to a 50 ml round-bottom flask and lyophilized to give 26 mg (27%) of the product as a white solid. LC / MS(SC BASE)t R 1.77min, purity 99%, mass found [M+H] + 430. Figure 18 1 H NMR(400MHz,chloroform-d)δ6.73(t,J=5.4Hz,1H),3.68(d,J=14.1Hz,2H),3.63(s,4H),3.59(d,J=10.3Hz,2H),3.57-3.52(m,4H),3 .45(q,J=5.3Hz,2H),2.90(t,J=5.1Hz,2H),2.69(t,J=6.9Hz,2H),2.48(t,J=6.9Hz,2H),2.16(bs,2H),1.51(s,6H),1.27(s,6H).
[0141] [Example 12: 2,5-dioxopyrrolidin-1-yl (3,3,6,6 tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6Synthesis of (thiepan-1-ylidene)carbamate [ka] N,N'-disuccinimidyl carbonate (52 mg, 0.20 mmol, 2 equiv.) was placed in an 8 mL screw-cap vial and dissolved in acetonitrile (2 mL). 6 A solution of -thiepine 1-oxide (20 mg, 0.1 mmol) in acetonitrile (1 ml) was added dropwise using a syringe. The mixture was stirred at room temperature for 1 h. The mixture was diluted with a mixture of diethyl ether (15 ml) and ethyl acetate (15 ml) and quenched with water. The organic layer was washed again with water, followed by brine, dried over Na2SO4, and concentrated under reduced pressure to give 117 mg of crude product as a white solid. The residue was purified by flash column chromatography (silica, 4 g; 20-50% EtOAc in heptane) and the product fractions were combined and concentrated under reduced pressure to give 49 mg (43%) of product as a white fluffy solid. LC / MS(SC BASE)t R 1.97min, purity 95%, mass found [M+Na] + 363, [2M+Na] + 703. 1 H NMR (400 MHz, chloroform-d) δ 3.92 (d, J = 14.2 Hz, 2H), 3.45 (d, J = 14.2 Hz, 2H), 2.80 (s, 4H), 1.52 (s, 6H), 1.29 (s, 6H).
[0142] TMTHSI proved to be stable during storage. Compound 12 was stored as a powder at atmospheric pressure in both light and darkness. 1 H-NMR en LC / MS (SC BASE) demonstrated that the compound did not deteriorate even after 4 months of storage.
[0143] [Example 13: 2,2,2-trifluoro-N-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 Synthesis of (thiepin-1-ylidene)acetamide [ka] An 8 ml screw-cap vial was charged with TMTHSI (50 mg, 0.25 mmol) and the material was dissolved in acetonitrile (2 ml). K2CO3 (69 mg, 0.50 mmol, 2 equiv) was added followed by trifluoroacetic anhydride (38 μl, 0.27 mmol, 1.1 equiv). The mixture was stirred at room temperature for 1 h. The mixture was diluted with diethyl ether and washed with water (2×). The organic phase was washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give 56 mg of crude product as a white solid.
[0144] The residue was purified by preparative RP-MPLC (Liberalis Prep, LUNA C18, 20-60% MeCN in water, 0.1% (v / v) formic acid). The product fractions were combined and lyophilized to give 35 mg (47%) of the product as a white solid. LC / MS(SC BASE)t R 2.18min, purity 99.0%, mass found [M+H] + 296. 1 H NMR (400 MHz, chloroform-d) δ 3.86 (d, J = 14.1 Hz, 2H), 3.66 (d, J = 14.1 Hz, 2H), 1.57 (s, 6H), 1.33 (s, 6H).
[0145] [ka] [Example 14: 1-(2-(2-hydroxyethoxy)ethyl)-3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1γ 6 Synthesis of (thiepin-1-ylidene)urea An 8 mL screw-cap vial was charged with 2-(2-amino-ethoxy)ethanol (29 μL, 0.29 mmol, 2 equiv.) and diisopropylethylamine (63 μL, 0.36 mmol, 2.5 equiv.) and dissolved in dichloromethane (2 mL). 6 A suspension of 2-thiepan-1-ylidene)carbamate (49 mg, 0.14 mmol) in dichloromethane (1 ml) was added slowly via pipette and the mixture was stirred at room temperature for 16 h. The mixture was diluted with water and extracted with dichloromethane (3x) and each organic phase was filtered through a phase separator. The combined organic extracts were concentrated under reduced pressure to give 43 mg of crude product. The residue was purified by preparative RP-MPLC (Liberalys, XSelect 10-50% MeCN in water, 10 mM NH4HCO3, pH=9.5) and the product fractions were combined and lyophilized to give 12 mg (25%) of product as a fluffy solid. LC / MS(SC BASE)t R 1.73min, purity 94%, mass found [M+H] + 331. 1 H NMR (400 MHz, chloroform-d) δ 5.41-5.30 (m, 1H), 3.84-3.75 (m, 2H), 3.75-3.70 (m, 2H), 3.60-3.53 (m, 4H), 3.48 (d, J = 14.1 Hz, 2H), 3.43-3.34 (m, 2H), 1.49 (s, 6H), 1.27 (s, 6H).
[0146] [ka] [Example 15: 3-(N-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 Synthesis of methyl thiepin-1-ylidene sulfamoyl benzoate In an 8 ml screw cap vial, add 1-imino-3,3,6,6-tetramethyl-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ 6 -thiepine 1-oxide (57 mg, 0.28 mmol) was charged and dissolved in dichloromethane (1.5 ml), pyridine (50 μl, 0.62 mmol, 2.16 equiv) was added and the mixture was stirred for 15 min. Methyl 3-(chlorosulfonyl)benzoate (81 mg, 0.34 mmol, 1.5 equiv) was added and the mixture was stirred at room temperature for 3 h. The mixture was quenched with 0.1 N aqueous HCl (15 ml) and extracted (3×) with dichloromethane, each organic extract was filtered through a phase separator. The combined extracts were concentrated under reduced pressure to give 100 mg of crude product as an oily residue. The residue was purified by preparative RP-MPLC (Liberaris, LUNA-C18, 30–70% aqueous MeCN, 0.1% (v / v) formic acid). The product fractions were combined and lyophilized to give 39 mg (34%) of the product as a white fluffy solid. LC / MS(SC BASE)t R 2.16min, 100% purity, mass found [M+H] + 398. 1 H NMR(400MHz,chloroform-d)δ8.65-8.61(m,1H),8.21(d,J=7.8Hz,1H),8.17(d,J=7.9Hz,1H),7.58(t,J =7.8Hz,1H),4.08(d,J=14.3Hz,2H),3.95(s,3H),3.41(d,J=14.2Hz,2H),1.49(s,6H),1.28(s,6H).
[0147] [ka] [Example 16: 3-(N-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 Synthesis of 1-thiepin-1-ylidene)sulfamoyl)benzoic acid 3-(N-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ) 6 The raw material was dissolved in THF (0.5 ml) and charged with 1,2-thiepin-1-ylidene)sulfamoyl)benzoate (29 mg, 73 μmol). A solution of LiOH·HO (7 mg, 167 μmol, 2.3 equiv.) in water (0.5 ml) was added. The resulting mixture was stirred at room temperature for 16 h. The reaction mixture was purified by preparative Rp-MPLC (Liberalys, LUNA-C18, 30–70% MeCN in water, 0.1% (v / v) formic acid). The product fractions were combined and lyophilized to give 26 mg (93%) of the product as a white fluffy solid. LC / MS(SC BASE)t R 1.70min, purity 98%, mass found [M+H] + 384. 1 H NMR (400MHz, chloroform-d) δ8.70(t,J=1.8z,1H),8.26(d,J=7.7Hz,1H),8.22(d,J=7.8Hz,1H),7. 62(t,J=7.8Hz,1H),4.10(d,J=14.3Hz,2H),3.42(d,J=14.2Hz,2H),1.49(s,6H),1.29(s,6H).
[0148] [ka] [Example 17: 3,3,6,6-tetramethyl-1-(methylimino)-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ 6 -Synthesis of thiepin 1-oxide] 1-Imino-3,3,6,6-tetramethyl-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ6-thiepine 1-oxide (50 mg, 0.25 mmol) was placed in an 8 ml screw-cap vial and dissolved in THF (1 ml), and the solution was treated with KOtBu (1.7 M in THF; 200 μl, 1.35 equiv). The resulting suspension was stirred for 5 min, then iodomethane (30 μl, 0.48 mmol, 1.9 equiv) was added and the mixture was stirred at room temperature for 2 h. The mixture was diluted with diethyl ether and quenched with water. The phases were separated and the aqueous phase was extracted (2×) with diethyl ether. The combined organic layers were washed with brine, dried over Na2SO4 and concentrated under reduced pressure to give 44 mg of crude product as a clear oil. The residue was purified by preparative RP-MPLC (Liberalys, XSelect 10-50% MeCN in water, 10 mM NH4HCO3, pH=9.5) and the product fractions were combined and concentrated under reduced pressure. The residue was diluted with acetonitrile and lyophilized to give 31.3 mg (58%) of the product as a white solid. LC / MS(SC BASE)t R 1.79min, purity 99%, mass found [M+H] + 214. 1 H NMR (400MHz, chloroform-d) δ3.32(d,J=13.9Hz,2H),3.07(d,J=14.0Hz,2H),2.84(s,3H),1.43(s,6H),1.28(s,6H).
[0149] [ka] [Example 18: 4-((3,3,6,6-tetramethyl-1-(methylimino)-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ 6 Synthesis of methyl 2-thiepinyl benzoate 3,3,6,6-Tetramethyl-1-(methylimino)-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ in an 8 mL screw cap vial 6-thiepine 1-oxide (31 mg, 0.14 mmol) was dissolved in anhydrous THF (1 ml). LiHMDS (1 M in THF; 174 μl, 0.17 mmol, 1.2 equiv.) was added and the mixture was stirred at room temperature for 15 min. Then, methyl 4-(bromomethyl)benzoate (50 mg, 0.22 mmol, 1.5 equiv.) was added and the mixture was stirred at room temperature for 20 h. The mixture was quenched in water and extracted with diethyl ether (3 × 10 ml). The combined organic phase was washed with brine and concentrated under reduced pressure to give a semi-solid residue. The residue was purified by preparative RP-MPLC (Liberasys, LUNA-C18, 30–70% MeCN in water, 0.1% (v / v) formic acid). The product fractions were combined and lyophilized to give 9 mg (17%) of the product as a white fluffy solid. LC / MS(SC BASE)t R 2.20min, purity 97%, mass found [M+H] + 362. 1 H NMR (400MHz, chloroform-d) δ7.97(d,J=8.2Hz,2H),7.43(d,J=8.2Hz,2H),6.72(d,J=15.7Hz,1H),6.25(d,J=15.8Hz,1H ),3.91(s,3H),3.81-3.69(m,1H),3.02(d,J=12.8Hz,1H),2.83-2.76(m,4H),1.44(s,3H),1.39(s,3H),1.37(s,6H).
[0150] [ka] [Example 19: Methyl 4-(((3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 Synthesis of -thiepin-1-ylidene)amino)methyl)benzoate 1-Imino-3,3,6,6-tetramethyl-4,5-didehydro-2,3,6,7-tetrahydro-1H-1λ in an 8 ml screw cap vial 6-thiepine 1-oxide (75 mg, 0.37 mmol) was taken up and dissolved in anhydrous THF (1.5 ml). KOtBu (1.7 M in THF; 280 μl, 0.47 mmol, 1.26 equiv) was added and the resulting mixture was stirred at room temperature for 15 min. To the resulting suspension was added methyl-4(bromomethyl)benzoate (129 mg, 0.56 mmol, 1.5 equiv) and the mixture was stirred at room temperature for 6 h. The mixture was quenched with water and extracted with diethyl ether (3 × 15 ml), and the combined organic extracts were washed with brine, dried over Na2SO4, and concentrated under reduced pressure to give 128 mg of crude product as a semi-solid residue. The residue was purified by preparative RP-MPLC (Liberalys, LUNA C18, 30–70% MeCN in water, 0.1% (v / v) formic acid). The product fractions were combined and lyophilized to give 28 mg (21%) of the product as an oily residue. LC / MS(SC BASE)t R 2.14min, purity 86%, mass found [M+H] + 348. 1 H NMR (400MHz, chloroform-d) δ7.99(d,J=8.3Hz,2H),7.46(d,J=8.0Hz,2H),4.39(s,2H),3 .91(s,3H),3.35(d,J=14.0Hz,2H),3.18(d,J=14.1Hz,2H),1.45(s,6H),1.28(s,6H).
[0151] [ka] [Example 20: Synthesis of tert-butyl (2-((2-aminoethyl)disulfanyl)ethyl)carbamate] A 250 ml round bottom flask was charged with bis-(2-aminoethyl) disulfide dihydrochloride (1.49 g, 6.62 mmol) and MeOH (75 ml). Triethylamine (2.89 ml, 20.8 mmol, 3.15 equiv) was added and when all solids had dissolved, di-tert-butyl dicarbonate (1.45 g, 6.64 mmol, 1 equiv) was added. The mixture was stirred at room temperature for approximately 1 hour.
[0152] Aqueous 1M NaH2PO4 (50ml) was added to quench the mixture and the organic solvent was removed by evaporation. The aqueous residue was washed with diethyl ether (3 x 30ml) and then made alkaline using aqueous 1N NaOH (~70ml). The aqueous mixture was extracted with diethyl ether (3 x 60ml). The combined organic extracts were dried over Na2SO4 and concentrated under reduced pressure to give 0.71g of a colourless oil. The aqueous layer was further extracted with dichloromethane (3 x 50ml) and the combined organic extracts were dried over Na2SO4 and concentrated in the previously isolated amount to give 0.78g (46%) of product as a clear thick oil. LC / MS(SC BASE)t R 1.83min, purity 98%, mass found [M+H] + 253. 1 H NMR (400 MHz, chloroform-d) δ 4.93 (s, 1H), 3.53–3.39 (m, 2H), 3.03 (t, J = 6.2 Hz, 2H), 2.84–2.74 (m, 4H), 1.62 (s, 2H), 1.45 (s, 9H).
[0153] [ka] [Example 21: Synthesis of 2,2-dimethyl-4,13-dioxo-3-oxa-8,9-dithia-5,12-diazahexadecan-16-oic acid] A 250 ml round bottom flask was charged with tert-butyl (2-((2-aminoethyl)di-sulfanayl)ethyl)carbamate (0.78 g, 3.09 mmol) and the material was dissolved in dichloromethane (25 ml). DMAP (0.11 g, 0.93 mmol, 0.3 equiv) was added followed by succinic anhydride (0.3 g, 3.09 mmol, 1 equiv). The resulting mixture was stirred at room temperature for 1 h. The mixture was quenched with 1N aqueous KHSO4 (30 ml), the phases were separated and the organic phase was washed with 1N aqueous KHSO4 (~30 ml). The combined aqueous phase was extracted with dichloromethane (30 ml) and the combined organic phase was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to give 1.02 g (94%) of the crude product as a solid. LC / MS(SC ACID) R 1.80min, 100% purity, mass found [M+Na] + 375, [MH] - 351. 1 H NMR(400MHz,chloroform-d)δ11.57(bs,1H),7.02(t,J=5.9Hz,1H),5.07(t,J=6.3Hz,1H),3.59(q,J=5.9Hz,2H),3.5 3-3.34(m,2H),2.86(t,J=6.0Hz,2H),2.77(t,J=7.2Hz,2H),2.73-2.66(m,2H),2.64-2.47(m,2H),1.45(s,9H).
[0154] [ka] [Example 22: Synthesis of 4-((2-((2-aminoethyl)disulfanayl)ethyl)amino)-4-oxobutanoic acid trifluoroacetate] A 250 mL round bottom flask was charged with 2,2-dimethyl-4,13-dioxo-3-oxa-8,9-dithia-5,12-diazahexadecan-16-oic acid (1.02 g, 2.89 mmol). This material was dissolved in dichloromethane (5 mL) and treated with trifluoroacetic acid (3 mL, 39.2 mmol, 13.5 equiv). The reaction was stirred at room temperature for approximately 1 hour. The reaction was concentrated under reduced pressure and coevaporated with toluene, dichloromethane, and diethyl ether to give 1.4 g (132%). The residue was dissolved in water and washed with dichloromethane (3×). The aqueous layer was lyophilized to give 1.04 g (98%) of product as a thick clear oil. 1H NMR (400 MHz, methanol-d4) δ 3.51 (dt, J = 8.4, 6.4 Hz, 2H), 3.36-3.23 (m, 2H, consistent with residual methanol-d4 peaks), 2.99 (dq, J = 8.4, 6.1, 5.6 Hz, 2H), 2.86 (dt, J = 8.8, 6.6 Hz, 2H), 2.61 (dt, J = 8.5, 6.4 Hz, 2H), 2.49 (dt, J = 8.7, 6.5 Hz, 2H).
[0155] [ka] [Example 23: 4-oxo-4-((2-((2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 Synthesis of -thiepin-1-ylidene)ureido)ethyl)disulfanayl)ethyl)amino)butanoic acid 2,5-dioxopyrrolidin-1-yl(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ) in an 8 mL screw cap vial 6 -thiepan-1-ylidene)carbamate (98 mg, 0.29 mmol) and the material was suspended / dissolved in acetonitrile (1 ml). DIPEA (115 μl, 0.66 mmol, 2.3 equiv) was added followed by a solution of 4-((2-((2-aminoethyl)disulfanayl)ethyl)amino)-4-oxobutanoic acid TFA-salt (113 mg, 0.31 mmol, 1.07 equiv) in water (0.5 ml) to form a suspension. Excess acetonitrile (0.5 ml) was added and the mixture was stirred at room temperature for 20 h.
[0156] The reaction mixture was purified by preparative RP-MPLC (Liberalis Prep, LUNA-C18, 10-50% aqueous MeCN in water, 0.1% (v / v) formic acid). The product fractions were combined and lyophilized to give 38 mg (28%) of product. LC / MS (SC_ACID) R 1.77 min, purity 96%, mass found [M+H]+ 478. 1 H NMR (400 MHz, chloroform-d) δ 7.73 (s, 1H), 6.52 (s, 0.2H), 6.00 (s, 0.8H), 3.91-3.76 (m, 2H), 3.58-3.38 (m, 6H), 2.92-2.73 (m, 4H), 2.59-2.36 (m, 4H), 1.49 (s, 6H), 1.31 (s, 6H).
[0157] [ka] [Example 24: 2,5-dioxopyrrolidin-1-yl 4-oxo-4-((2-((2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 Synthesis of -thiepin-1-ylidene)ureido)ethyl)disulfanayl)ethyl)amino)butanoate] 4-oxo-4-((2-((2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ) in an 8 mL screw cap vial 6 N-thiepin-1-ylidene)ureido)ethyl)disulfanayl)ethyl)amino)butanoic acid (38.8 mg, 0.081 mmol) and dichloromethane (1 ml) were added. N-hydroxysuccinimide (13 mg, 0.11 mmol, 1.4 equiv) was added followed by EDC (22 mg, 0.11, 1.4 equiv). The mixture was stirred at room temperature for approximately 2 h. The mixture was concentrated under reduced pressure and the resulting white foam was purified by preparative RP-MPLC (Liberalis Prep, LUNA-C18, 20-60% MeCN in water, 0.1% (v / v) formic acid). The product fractions were combined and lyophilized. The lyophilized material was dissolved in dichloromethane and transferred to an 8 ml brown glass vial and the solvent was evaporated under a stream of N2 and coevaporated with diethyl ether to give 35 mg (76%) of product. LC / MS(SC ACID) R 1.86min, purity 93%, mass found [M+H] + 575. 1 H NMR (400MHz, chloroform-d) δ6.73(s,1H),5.32(t,J=6.1Hz,1H),3.78(d,J=14.1Hz,2H),3 .58(q,J=6.1Hz,2H),3.53-3.41(m,4H),3.00(t,J=7.1Hz,2H),2.89~2.76(m,8H),2.67 (t,J=7.1Hz,2H),1.47(s,6H),1.28(s,6H).
[0158] [ka] Example 25: Coupling of TMTHSI-disulfide NHS ester to siRNA oligonucleotides Preparation of TMTHSI-NHsiRNAPLK1 A 2 mL UPLC vial was charged with siRNA PLK1 oligonucleotide (5 mg, 0.36 μmol) and borate buffer pH 8.4 (250 μl) was added. A 20 mM DMSO stock solution of 2,5-dioxopyrrolidin-1-yl 4-oxo-4-((2-((2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)ureido)ethyl)disulfanayl)ethyl)amino)butanoate was prepared and 5 equivalents (90 μl, 1.04 mg, 1.8 μmol) of the stock solution was added to the siRNA-containing solution with stirring. The mixture was stirred at room temperature and monitored by UPLC. An excess of 5 equivalents of 2,5-dioxopyrrolidin-1-yl 4-oxo-4-((2-((2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6After addition of 2,5-dioxopyrrolidin-1-yl 4-oxo-4-((2-((2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ-thiepin-1-ylidene)ureido)ethyl)disulfanayl)ethyl)amino)butanoate (90 μl, 1.04 mg, 1.8 μmol) and further stirring, the reaction showed >90% conversion to TMTHSI-NH-siRNAPLK1. The final crude product was purified with PD-10 (buffer exchange into phosphate buffer pH 7.4) and Vivaspin (5000 Da molecular weight cut-off (MWCO), 4000 g, pH 7.4 phosphate buffer 3 times, final concentration step) to remove excess TMTHSI-NHS 2,5-dioxopyrrolidin-1-yl 4-oxo-4-((2-((2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ-thiepin-1-ylidene)ureido)ethyl)disulfanayl)ethyl)amino)butanoate (90 μl, 1.04 mg, 1.8 μmol) and further stirring. 6 -thiepin-1-ylidene)ureido)ethyl)disulfanayl)ethyl)amino)butanoate was removed. The final solution of TMTHSI-NH-siRNA PLK1 (1000 μl) was transferred to a 2 mL UPLC vial and stored at +4° C.
[0159] [ka] Example 26: Coupling of azido-CPP1 peptide to TMTHSI-NH-siRNA oligonucleotide Preparation of CPP1-TMTHSI-NH-siRNA PLK1 conjugate First, a stock solution of azido-CPP1 peptide (0.49 mg, 0.35 μmol) in acetonitrile / water (1:1 by volume, 100 μl) was prepared. First, 50 μl of the stock solution (0.5 equiv., 0.25 mg, 0.18 μmol) was added to a 2 mL UPLC vial containing TMTHSI-NH-siRNA PLK1 (0.35 μmol in 1000 μl pH 7.4 phosphate buffer). The mixture was stirred at room temperature and monitored by UPLC. After 30 min, all of the azido-CPP1 peptide was converted and the other half of the azido-CPP1 peptide stock solution was added (0.5 equiv., 0.25 mg, 0.18 μmol). After stirring for another 30 min, the reaction for CPP1-TMTHSI-NH-siRNA PLK1 was fully converted. The final crude product was washed (5000 Da molecular weight cutoff (MWCO), 4000 g, pH 7.4 phosphate buffer three times, final concentration step) and concentrated in a Vivaspin centrifuge tube. The final solution of CPP1-TMTHSI-NHsiRNA PLK1 (750 μl) was transferred to a 2 mL UPLC vial.
[0160] [ka] Example 27: Coupling of acid labile linker 7 to CPP1-TMTHSI-siRNA oligonucleotide Preparation of linker 7-CPP1-TMTHSI-NH-siRNA PLK1 conjugate A solution of CPP1-TMTHSI-NH-siRNA PLK1 (750 μl) was transferred to a Vivaspin centrifuge tube and buffer exchanged into pH 8.4 borate buffer (5000 Da MWCO, 4000 g, pH 8.4 borate buffer 3 times, final concentration step). Final volume after Vivaspin: 1200 μl. A 20 mM DMSO stock solution of hydrazone MA linker NHS ester (Linker 7) was prepared. With stirring, 5 equivalents of hydrazone MA linker NHS ester stock solution in DMSO (66 μl, 0.73 mg, 1.6 μmol) was added to CPP1-TMTHSI-siRNA (0.32 μmol) in borate buffer (1000 μl) at room temperature and monitored by UPLC. After 45 min, the reaction showed complete conversion to the Linker 7-CPP1-TMTHSI-siRNA PLK1 conjugate. The final crude conjugate was purified on PD-10 (5000 Da molecular weight cutoff (MWCO), 4000 g, buffer exchanged into pH 7.4 phosphate buffer) and Vivaspin (5000 Da molecular weight cutoff (MWCO), 4000 g, pH 7.4 phosphate buffer three times, final concentration step) to remove excess hydrazone MA linker NHS ester.
[0161] [ka] [Example 29: Synthesis of (S)-15-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-2,2-dimethyl-4,12-dioxo-3,8-dioxa-5,11-diazahexadecan-16-oic acid (product isolated as a mixture of α / γ positional isomers)] Folic acid (1.84 g, 4.17 mmol) was suspended in anhydrous dimethylsulfoxide (15 ml) and the flask was placed in a sand bath at 100° C. until a solution was formed. The solution was then cooled to room temperature and N-hydroxysuccinimide (503 mg, 4.37 mmol, 1.05 equiv.) was added, followed by a solution of N-Boc-2-(2-amino-ethoxy)-ethylamine (852 mg, 4.17 mmol) in anhydrous dimethylsulfoxide (3 ml). The mixture was stirred for 10 min, then EDC (840 mg, 4.38 mmol, 1.05 equiv.) was added and the mixture was stirred at room temperature for 17 h.
[0162] The reaction mixture was purified (7 runs) by preparative RPMPLC (Liberalis, XSelect 5-30% MeCN in water, 10 mM NH4HCO3, pH=9.5). The product fractions were combined and partially concentrated under reduced pressure. The resulting residue was lyophilized to give 0.91 g (34%) of product. LC / MS(SC BASE)t R 1.37min, purity 100%, mass found [MH] - 626. 1 H NMR(400MHz,DMSO-d6+D2O)δ8.66(s,1H),7.99(q,J=4.9Hz,1H),7.65(dd,J=11.6,8.5Hz,2H),6.75(d,J= 6.1Hz,1H),6.67(dd,J=9.0,2.7Hz,2H),4.52(s,2H),4.33(dd,J=8.9,4.8Hz,0.4H),4.19(dd,J=8.1,4.7 Hz,0.6H),3.45-3.31(m,4H),3.26-3.13(m,2H),3.11-3.01(m,2H),2.26(t,J=7.1,6.4Hz,1H),2.15(t,J=8.0Hz,1H),2.08-1.82(m,2H),1.35 and 1.33(2×s,combined 9H).
[0163] [ka] [Example 30: N 2-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzoyl)-N 5 Synthesis of -(2-(2-aminoethoxy)ethyl)-L-glutamine (product isolated as a mixture of α / γ positional isomers) (S)-15-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzamido)-2,2-dimethyl-4,12-dioxo-3,8-dioxa-5,11-diazahexadecan-16-oic acid (403 mg, 0.64 mmol) was dissolved in trifluoroacetic acid (2 ml, 26.0 mmol) and the resulting mixture was stirred at room temperature for 25 min. The reaction mixture was concentrated under reduced pressure and the residue was coevaporated with dichloromethane (2×). The residue was taken up in N,N-dimethylformamide (1 ml) and warmed until completely dissolved, then allowed to cool to room temperature. The solution was treated with triethylamine (3×200 μl) to give an orange precipitate. The mixture was diluted with acetone and the solid was collected by filtration. The residue was washed with acetone (3×) and air-dried to give 346 mg (97%) of the product as an orange solid. 1 H NMR(400MHz,DMSO-d6)δ8.66-8.57(m,1H),8.24(t,J=5.5Hz,0.6H),8.07(t,J=5.6Hz,0.4H),7.72-7.62(m,1H),7.62-7.51(m,1H),7.30(bs ,2H),6.91(q,J=6.1Hz,1H),6.63(t,J=7.6Hz,2H),4.52-4.38(m,2H),4.30(q,J=6.3Hz,0.4H),4.10(q,J=6.4Hz,0.6H),3.55(q,J=6.2,5.6 Hz,3H),3.43(bs,3H),3.31-3.13(m,4H),2.94(q,J=6.2,5.8Hz,2H),2.21-2.11(m,2H),2.06-1.79(m, 3H),0.97(t,J=7.2Hz,1H).
[0164] NMR shows a very broad HOD signal below the signal from 4.5 to 2.5 ppm.
[0165] [ka] [Example 31: N 2 -(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzoyl)-N 5 -(2-(2-(3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 Synthesis of (1-thiepin-1-ylidene)ureido)ethoxy)ethyl)-L-glutamine (product isolated as a mixture of α / γ positional isomers) N 2 -(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl)amino)benzoyl)-N 5 -(2-(2-aminoethoxy)ethyl)-L-glutamine (90.3 mg, 0.13 mmol) was dissolved in hot dimethylsulfoxide (1.5 ml) and allowed to cool to room temperature. Triethylamine (107 μl, 0.77 mmol, 6 eq) was added and the resulting mixture was diluted with 2,5-dioxopyrrolidin-1-yl(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ) and diluted with 1,2,3,4,4-trimethyl-1,3,4,5 ... 6 -thiepan-1-ylidene)carbamate (52 mg, 0.15 mmol, 1.2 equiv.) was added to the reaction mixture, which was stirred at room temperature for 4 days.
[0166] The reaction mixture was purified by preparative RP-MPLC (Liberalys, XSelect 5-40% MeCN in water, 10 mM NH4HCO3, pH = 9.5). The product fractions were combined and lyophilized to give 51 mg (53%) of product. LC / MS(SC BASE)t R 1.45min, purity 99%, mass found [M+H] + 753. 1H NMR(400 MHz,DMSO-d6+D2O)δ8.66(s,1H),8.02~7.90(m,1H),7.70-7.59(m,2H),6.72-6.61(m,3H),4 .50(s,2H),4.37-4.32(m,0.4H),4.22-4.13(m,0.6H),3.90-3.79(m,2H),3.59(dd,J=14.0,4 .5Hz,2H),3.44-3.30(m,5H),3.25-3.14(m,2H),3.09(t,J=5.8Hz,2H),2.26(t,J=7.7Hz,1H) ,2.15(t,J=7.6Hz,1H),2.05-1.93(m,1H),1.90(d,J=13.5Hz,1H),1.33(s,6H),1.19(s,6H).
[0167] Example 32: Coupling of TMTHSI-containing linker folate to azide-containing nanoparticles (CriPec) [ka] Folate-labeled core-crosslinked polymeric micelles were generated by conjugating folate to the surface of the polymeric micelle shell and used for targeting studies. To enable folate conjugation by click chemistry, azide-functionalized polymeric micelles were prepared essentially following a reported protocol [Hu et al., Biomaterials. 2015;53:370-8]. However, a portion of the azide-functionalized block copolymer (22 kDa, 10 mol% of crosslinker L2 [1], 5 w% of total block copolymer derivatized) was added next to a (95 w%) non-functionalized block copolymer (22 kDa, 10 mol% of crosslinker L2 [Biomaterials. 2015;53:370-8], 95 w% of total block copolymer derivatized). These two block copolymers were then mixed with azide-PEG 1000 ng / ml of ... 5000 The former was synthesized from -OH (azide-PEG 5000) was synthesized following the same procedure, except that 2-ABCPA initiator was used instead. The resulting azide-functionalized polymeric micelles were then purified in 20 mM ammonium acetate pH 5 buffer containing 130 mM NaCl, buffer exchanged into 20 mM sodium phosphate pH 7.4 buffer containing 130 mM NaCl, and concentrated to approximately 96 mg / mL polymer equivalents using tangential flow filtration (TFF) with a modified polyethersulfone (mPES) 100 kDa module (spectrumlabs). Folic acid was then conjugated to the concentrated azide-functionalized core-crosslinked polymeric micelles via copper-free click chemistry using the following procedure.
[0168] At room temperature (RT), DMSO (93 μL) was added to 200 μL of azide-functionalized modified core-crosslinked polymeric micelles (0.13 μmol azide equivalents) in an amber UPLC vial with stirring (300 rpm). After dissipating heat, folic acid (1.0 equiv., 0.13 μmol, 5 μL, Merachem) was added dropwise to the reaction mixture. The progress of the conjugation reaction was monitored by UPLC-UV for 4 h, after which the reaction was stopped. Based on UPLC, the conversion of folic acid was determined to be 45%. This corresponds to 2.3% of the core-crosslinked polymeric micelles labeled with folic acid.
[0169] [ka] [Example 33: Synthesis of 1-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ6-thiepin-1-ylidene)urea] Under N2 atmosphere, 2,5-dioxopyrrolidin-1-yl (3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 62,2'-(ethane-1,2-diylbis(oxy))bis(ethan-1-amine) (0.42 ml, 2.89 mmol, 5 equiv.) was added. The reaction was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure. The residue was taken up in a 1:1 mixture of acetonitrile / water (4 ml) and purified (in two portions) by preparative RP-MPLC (Liberalys, XSelect 10-50% MeCN in water, 10 mM NH4HCO3, pH=9.5). The product fractions were combined and lyophilized to give 156 mg (72%) of the product as a white fluffy solid. LC / MS(SC BASE)t R 1.67min, purity 99%, mass found [M+H] + 374. 1 H NMR(400MHz,DMSO-d6+D2O)δ3.86 (d,J=14.0Hz,2H),3.61(d,J=13.9Hz,2H),3.54-3.46(m,4H),3.40(q,J=6.0 Hz,4H),3.15-3.04(m,3H),2.67(t,J=5.7Hz,1H),1.34(s,6H),1.21(s,6H).
[0170] [ka] [Example 34: 1-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6 Synthesis of (thiepin-1-ylidene)urea-Cy7 adduct formate In an 8 mL screw-cap vial, place Cy7-NHS ester (95 mg, 0.13 mol) and 1-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-3-(3,3,6,6-tetramethyl-1-oxide-4,5-didehydro-2,3,6,7-tetrahydro-1λ 6A solution of 1-thiepin-1-ylidene)urea (66.5 mg, 0.18 mmol, 1.37 equiv) in MeCN (1.5 ml) was added and the mixture was stirred at room temperature for 2 h. The mixture was then stored at -20 °C overnight. The mixture was allowed to warm to room temperature and then purified by preparative MPLC (Liberalys Prep, LUNA-C18, 20-60% MeCN in water, 0.1% (v / v) formic acid). The product fractions were concentrated under reduced pressure and the residue was diluted with a small amount of MeCN and lyophilized overnight to give 95 mg (77%) of the product as a dark green solid. LC / MS(AN ACID DAY UV800) R 3.46min, purity 88%, mass found [M] + 905, [M+H] 2+ 453. 1 H NMR (400MHz, methanol-d4) δ8.37(s,1H),8.02-7.95(m,0.5H),7.75(dd,J=14.0,8.5Hz,1.5H),7.47(d,J=7.5Hz,2H),7 .43-7.34(m,1H),7.31-7.20(m,3H),7.15-6.92(m,1H),6.81-6.34(m,2H),6.24-6.09(m,1H),4.11(t,J=7.3Hz,1H) ,3.86(d,J=14.1Hz,2H),3.66-3.55(m,8H),3.55-3.45(m,5H),3.39-3.32(m,3H),3.29-3.21(m,2H),2.57(q,J=5.6 Hz,3H),2.50~2.28(m,1H),2.27~2.15(m,2H),2.00~1.89(m,2H),1.89~1.74(m,3H),1.75~1.61(m,10H),1.59~1.52 (m,2H),1.51~1.42(m,2H),1.40(s,7H),1.33~1.20(m,8H),1.03(s,1H).
[0171] [Measurement method] AN ACID DAY UV800, Instrument: Agilent 1260 Binary Pump: G1312B, degasser; autosampler, Colcom; DAD: Agilent G1315D, 210-800nm; MSD: Agilent LC / MSD G6130B ESI, pos / neg 100-1000; ELSD Alltech 3300 gas flow rate 1.5ml / min, gas temperature: 40℃; column: Waters XSelect(trademark) C18, 50x2.1mm, 3.5μ, temperature: 35℃, flow rate: 0.8mL / min, gradient: t0=5% A, t 3.5min =98% A,t 6min = 98% A, post time: 2 min; eluent A: 0.1% formic acid in acetonitrile, eluent B: 0.1% formic acid in water.
[0172] [MS parameters] Source: ESI, Capillary voltage: 3000V, Drying gas flow rate: 12L / min, Nebulizer pressure: 60psig, Drying gas temperature: 350℃, Fragment: 70, MS scan: MS range 100-1000 (positive / negative mode), Scan speed: 0.84sec / cycle.
[0173] Example 35: Kinetics of reaction between TMTHSI and benzyl azide to determine the reaction rate constant value kt. The kt values of the conversion of benzyl azide with BCN-OH and TMTHSI were investigated by monitoring the reaction by mass spectrometry. In this study, QTOF mass spectrometry coupled with an ESI source was utilized as the measurement method. In detail, alkynes (TMTSHI or BCN-OH in ACN / water / acetic acid (3:1:0.01%)) were reacted with 1.0 equivalent of benzyl azide and the reaction rate was measured using MS. The measurement results are included in Figure 55. The kt value of TMTHSI measured for reaction with benzyl azide is 0.83 M. -1 s -1 and BCN-OH (0.12M -1 S -1 ) is about 7 times faster.
[0174] [Cited documents] ·A. Krebs and H. Kimling, Tetrahedron Lett., 1970, 761-764. ·de Almeida, G., Sletten, E. M., Nakamura, H., Palaniappan, K. K., Bertozzi, C. R., Angew. Chem. Int. Ed., 2012, 51, 2443-2447 ·Li et al. Molecules, 2016, 21, 1393. ·Tota, A., Zenzola, M., Chawner, S. J., St John-Campbell, S., Carlucci, C. Romanazzi, G., Degennaro, L., Bull, J. A., Luisi, R., Chem. Commun., 2017, 53, 348-351. ·Hu et al. Biomaterials. 2015;53:370-8 ·King et al, Chem Comm, 2012, 48, 9308-9309. ·Dommerholt et al. Nature Communications 5, Article number: 5378 (2014) ·Dommerholt et al. Top Curr Chem (Z) 2016, 374:16.
[0175] (Supplementary Note) (Supplementary Note 1) The compound represented by formula (I). [Chemical Structure Diagram] n and m are independently 0, 1, or 2, and n + m = 2, X is O or NR 9 and Y is NR 10 and R 1 、R 2 、R3 , R 4 are independently hydrogen, halogens (F, Cl, Br, I), O, N, P and S, C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl group, The O, N, P and S each independently represent hydrogen, halogen (F, Cl, Br, I), C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Binds to a cycloalkyloxy group, the alkyl group is optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The alkyl group, (hetero)aryl group, alkyl(heteroaryl group) and (hetero)arylalkyl group are independently and optionally C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Substituted by one or more substituents selected from the group consisting of cycloalkyloxy groups, halogens (F, Cl, Br, I), amino groups, oxo groups and silyl groups; the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted; said alkyl, alkoxy, cycloalkyl and cycloalkyloxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The silyl group has the formula (R 11 )3Si-, where R 11 is independent, C 1 ~C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups and C3-C 12 cycloalkyloxy groups; the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkoxy groups are optionally substituted; the alkyl, alkoxy, cycloalkyl and cycloalkyloxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; R 5 , R 6 , R 7 , R 8 are independently hydrogen, halogens (F, Cl, Br, I), O, N, P and S, C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl group, The O, N, P and S each independently represent hydrogen, halogen (F, Cl, Br, I), C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Binds to a cycloalkyloxy group, the alkyl group is optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The alkyl group, (hetero)aryl group, alkyl(hetero)aryl group and (hetero)arylalkyl group are independently optionally selected from C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Substituted by one or more substituents independently selected from the group consisting of cycloalkyloxy groups, halogens (F, Cl, Br, I), amino groups, oxo groups, and silyl groups; the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted; said alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The silyl group has the formula (R 11 )3Si-, where R 11 is C1~C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups and C3-C 12 cycloalkyloxy groups; the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted; the alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; R 1 and R 7 , R 1 and R 8 , R 2 and R 7 , R 2 and R 8 , R 3 and R 5 , R 3 and R 6 , R 4 and R 5 , and / or R 4 and R 6 optionally, independently, form a fused ring system, such as a cycloalkyl-, cyclo(hetero)aryl-, cycloalkyl(hetero)aryl, -cyclo(hetero)arylalkyl system; the alkyl groups of said fused system are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The alkyl group, (hetero)aryl group, alkyl(hetero)aryl group, and (hetero)arylalkyl group of the condensed system are independently and optionally C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl group C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Substituted with one or more substituents independently selected from the group consisting of cycloalkyloxy groups, halogens, amino groups, oxo groups, and silyl groups; the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted; the alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; The silyl group has the formula (R 11 )3Si-, R 11 is C1~C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C1-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups and C3-C 12 cycloalkyloxy groups; the alkyl, alkenyl, alkynyl, cycloalkyl, alkoxy, alkenyloxy, alkynyloxy and cycloalkyloxy groups are optionally substituted; the alkyl, alkoxy, cycloalkyl and cycloalkoxy groups are optionally interrupted by one or more heteroatoms selected from the group consisting of O, N, P and S; R 9 , R 10 are independently hydrogen, halogen (F, Cl, Br, I), R 12 , -CH=C(R 12 )2, -C≡CR 12 , -[C(R 12 )2C(R 12 )2O]qR 12 (q ranges from 1 to 200), -CN, -N3, -NCX, -XCN, -XR 12 , -N(R 12 )2,- + N(R 12 )3, -C(X)N(R 12 )2, -C(R 12 )2XR 12, -C(X)R 12 , -C(X)XR 12 , -S(O)R 12 , -S(O)2R 12 , -S(O)OR 12 , -S(O)2OR 12 , -S(O)N(R 12 )2, -S(O)2N(R 12 )2, -OS(O)R 12 , -OS(O)2R 12 , -OS(O)OR 12 , -OS(O)2OR 12 , -P(O)(R 12 )(OR 12 ), -P(O)(OR 12 )2, -OP(O)(OR 12 )2, -Si(R 12 )3, -XC(X)R 12 , -XC(X)XR 12 , -XC(X)N(R 12 )2, -N(R 12 )C(X)R 12 , -N(R 12 )C(X)XR 12 and -N(R 12 )C(X)N(R 12 ) 2 selected from the group consisting of X is oxygen or sulfur and R 12 are independently hydrogen, halogen (F, Cl, Br, I), C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl groups.
[0176] (Appendix 2) The compound according to Appendix 1, wherein n is 1 and m is 1, and represented by formula (II): [ka] R 1 ~R 8 , X, and Y are as defined in Appendix 1.
[0177] (Appendix 3) X is 0 and / or R 10 is H.
[0178] (Appendix 4) R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 are independently H, halogen (F, Cl, Br, I) or C1-C 24 Alkyl, preferably R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 is independently H or C1-C4 alkyl.
[0179] (Appendix 5) R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 is a methyl group, or R 1 , R 2 , R 3 , R 4 , is a methyl group and R 5 , R 6 , R 7 , R 8 is H.
[0180] (Appendix 6) 6. The compound according to any one of appendices 1 to 5, wherein one atom of the thiocycloheptyne ring adjacent to the X and / or Y and / or S atom of the compound of formula (I) is independently bonded to an optional linking group (L) and functional group (Q) to give a compound of formula (III). (Formula (I))-LQ (III) The linking group (L) is absent or is a linear or branched C1-C 24 Alkylene group, C2-C 24 Alkenylene group, C2-C 24 Alkynylene group, C3-C 24 Cycloalkylene group, C5-C 24 Cycloalkenylene group, C5-C 24 Cycloalkynylene group, C7-C 24 Alkyl(hetero)arylene groups, C7-C 24 (Hetero)arylalkylene groups, C5-C 24 (Hetero)arylalkenylene group, C9-C 24 (hetero)arylalkynylene groups; The alkylene group, alkenylene group, alkynylene group, cycloalkylene group, cycloalkenylene group, cycloalkynylene group, alkyl(hetero)arylene group, (hetero)arylalkylene group, (hetero)arylalkenylene group, and (hetero)arylalkynylene group are optional and independently C1 to C 12 Alkyl groups, C2-C 12 Alkenyl groups, C2-C 12 Alkynyl groups, C3-C 12 Cycloalkyl groups, C5-C 12 Cycloalkenyl groups, C5-C 12 Cycloalkynyl groups, C8-C 12 Alkoxy group, C2-C 12 Alkenyloxy group, C2-C 12 Alkynyloxy groups, C3-C 12 Substituted with one or more substituents selected from the group consisting of cycloalkyloxy groups, halogens (F, Cl, Br, I), amino groups, oxo and silyl groups; The silyl group has the formula (R 11 )3Si, R 11 is defined as above, The functional group Q is hydrogen, halogen (F, Cl, Br, I), R 12 , -CH=C(R 12 )2, -C≡CR 12, -[C(R 12 )2C(R 12 )2O] q R 12 (q ranges from 1 to 200), -CN, -N3, -NCX, -XCN, -XR 12 , -N(R 12 )2,- + N(R 12 )3, -C(X)N(R 12 )2, -C(R 12 )2XR 12 ,-C(X)R 12 ,—C(X)XR 12 ,—S(O)R 12 , -S(O)2R 12 , -S(O)OR 12 , -S(O)2OR 12 , -S(O)N(R 12 )2, -S(O)2N(R 12 )2, -OS(O)R 12 , -OS(O)2R 12 , -OS(O)OR 12 , -OS(O)2OR 12 , -P(O)(R 12 )(OR 12 ), -P(O)(OR 12 )2, -OP(O)(OR 12 )2, -Si(R 12 )3, -XC(X)R 12 , -XC(X)XR 12 , -XC(X)N(R 12 )2, -N(R 12 )C(X)R 12 , -N(R 12 )C(X)XR 12 and -N(R 12 )C(X)N(R 12 ) 2 selected from the group consisting of X is oxygen or sulfur and R 12 are independently hydrogen, halogen (F, Cl, Br, I), C1-C 24 Alkyl groups, C6-C 24 (Hetero)aryl groups, C7-C 24 Alkyl (hetero)aryl groups and C7-C 24 (hetero)arylalkyl groups.
[0181] (Appendix 7) L is absent or [C(R 12 )2C(R 12 )2O] q -R 12 (q ranges from 1 to 200), -CN, -NCX, -XCN, -XR 12 , -N(R 12 )2,- + N(R 12 )3, -C(X)N(R 12 )2, -C(R 12 )2XR 12 ,-C(X)R 12 ,—C(X)XR 12 ,—S(O)R 12 , -S(O)2R 12 , -S(O)OR 12 , -S(O)2OR 12 , -S(O)N(R 12 )2, -S(O)2N(R 12 )2, -OS(O)R 12 , -OS(O)2R 12 , -OS(O)OR 12 , -OS(O)2OR 12 , -P(O)(R 12 )(OR 12 ), -P(O)(OR 12 )2, -OP(O)(OR 12 )2, -Si(R 12 )3, -XC(X)R 12 , -XC(X)XR 12 , -XC(X)N(R 12 )2, -N(R 12 )C(X)R 12 , -N(R 12 )C(X)XR 12 and -N(R 12 )C(X)N(R 12 )2, X is oxygen or sulfur and R 12 is as defined in Appendix 6, and / or Q is -OR 12 , -N(R 12 )2,- +N(R 12 )3, -C(O)N(R 12 )2, -C(O)OR 12 ,-OC(O)R 12 ,-OC(O)OR 12 ,-OC(O)N(R 12 )2, -N(R 12 )C(O)R 12 , -N(R 12 )C(O)OR 12 and -N(R 12 )C(O)N(R 12 ) 2 selected from the group consisting of R 12 is as defined in Appendix 6, A compound described in Appendix 6.
[0182] (Appendix 8) 8. The compound of claim 6 or 7, wherein the functional group Q is linked to one or more of a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle, or a carrier.
[0183] (Appendix 9) The compound according to any one of claims 6 to 8, including a compound of formula (I) which is coupled to an optional linking group (L) and functional group (Q) to form a compound of formula (III). (Formula (I))-LQ (III) Formula (I) is linked to an optional linking group (L) and a functional group (Q) at the Y atom; m and n are both 1, X is O, R 1 , R 2 , R 3 , R 4 are the same and are selected from the group consisting of H and C1-C4 alkyl; R 5 , R 6 , R 7 , R 8 are the same and are selected from the group consisting of H and C1-C4 alkyl; Y is NR 10 By this, R 10is replaced by LQ, L is absent or a chain of 1 to 25 atoms, preferably 1 to 15 atoms, in length, containing one or more, preferably 1 to 6 moieties independently selected from the group consisting of -S(O)2-, -S-, -SS-, -C(O)NH-, -NHC(O)-, -C(O)O- and phenylene, whereby the length of said chain is determined by the number of atoms in the longest linear chain of atoms, and Q includes alcohols, amines, thiols, carboxylates, carboxylic acids or activated esters, ketones, aldehydes, nitriles, maleimides, alkenes, alkynes, heteroaromates, leaving groups, and phosphoramidites.
[0184] (Appendix 10) 10. The compound of any one of claims 6 to 9, wherein the functional group Q has been reacted with a molecule of interest, preferably a molecule selected from the group consisting of a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle and a carrier.
[0185] (Appendix 11) A compound comprising a compound according to any one of claims 1 to 10 bound to a compound comprising a 1,3-dipole or a 1,3-(hetero)diene. the alkyne group of the thiocycloheptyne of formula (I) is attached to the 1,3-dipole or 1,3-(hetero)diene-containing compound; The compound containing a 1,3-dipole or a 1,3-(hetero)diene is preferably an azide-containing compound, a nitrone-containing compound or a nitrile oxide-containing compound, more preferably an azide-containing compound and an azide-alkyne coupling; Preferably, this results in the formation of a triazole compound, Preferably, the 1,3-dipole or 1,3-(hetero)diene containing compound comprises one or more of a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle and a carrier.
[0186] (Appendix 12) A method for coupling a compound according to claims 1 to 10 with a compound containing a 1,3-dipole or a 1,3-(hetero)diene, comprising the steps of: Preferably, the 1,3-dipole or 1,3-(hetero)diene containing compound is an azide-containing compound, a nitrone-containing compound or a nitrile oxide-containing compound, preferably an azide-containing compound; Preferably, the coupling is a copper-free click reaction, and preferably, the 1,3-dipole or 1,3-(hetero)diene containing compound is one or more of a drug, an antibody, a protein, a peptide, a ligand, an imaging label, a targeting ligand, a delivery agent, a nanoparticle, a carrier. method.
[0187] (Appendix 13) 1. A method for preparing a construct comprising nanoparticles, comprising: the nanoparticles are preferably self-assembled polymeric micelles from a thermosensitive block copolymer and an active compound selected from the group of drugs, antibodies, proteins, peptides, ligands, imaging labels, targeting ligands, delivery agents, nanoparticles, and carriers; Coupling of the nanoparticles with the active compound preferably comprises coupling of a compound according to any one of claims 1 to 8 with an azide-containing compound to form a triazole compound, The nanoparticles are the azide-containing compound and the active compound comprises a compound as defined in any one of appendices 1 to 8, or the nanoparticles comprise a compound as defined in any one of appendices 1 to 8 and the active compound comprises the azide-containing compound; method.
[0188] (Appendix 14) X is O, Y is NH, m and n are both 1, R 1 ~R 4 is methyl, R 5 -R 8 is hydrogen, a. converting bishydrazone (2) to iminodidehydrosulfonimino (3); [ka] b. isolating the resulting iminodidehydrosulfonimino (3); A method comprising:
[0189] (Appendix 15) The conversion comprises an oxidation reaction in which the bishydrazone (2) is reacted with an oxidizing agent to oxidize the sulfur functionality to a sulfonimino functionality; Preferably, the conversion further comprises an oxidation reaction in which the bishydrazone (2) is reacted with an oxidizing agent to oxidize the hydrazone functionality to an alkyne functionality.
[0190] (Appendix 16) 15. The method of claim 14, wherein the oxidation reaction is a two-step reaction, preferably the oxidation reaction is a one-pot reaction with one oxidizing agent, preferably iodobenzene diacetate.
[0191] (Appendix 17) 10. Use of a compound according to any one of claims 1 to 9 in a method of coupling two molecules of interest, said molecules being optionally independently selected from among drugs, antibodies, proteins, peptides, ligands, imaging labels, targeting ligands, delivery agents, nanoparticles, and carriers for targeted and / or labeled delivery systems such as nanoparticles, proteins, hydrogels, liposomes, antibody drug conjugates, drug polymer conjugates, etc. use.
[0192] (Appendix 18) Use of the compounds according to appendix 1 to 9 in bioorthogonal, optionally copper-free click reactions.
[0193] (Appendix 19) Use of a compound according to claims 1 to 9 in a method of coupling nanoparticles to one or more of drugs, antibodies, proteins, peptides, ligands, imaging labels, targeting ligands, delivery agents, nanoparticles, and carriers using a copper-free click reaction.
Claims
1. A compound represented by formula (II): 【Chemistry 1】 R 1 , R 2 , R 3 and R 4 is a methyl group, R 5 , R 6 , R 7 , R 8 and R 10 is hydrogen.
2. A compound represented by formula (III), which is formed by bonding one atom of the thiocycloheptyne ring adjacent to the N atom or the S atom of the compound according to claim 1 to a functional group (Q) via an optional linker (L). (Formula II)-L-Q (III) (Formula II) is the formula (II) described in claim 1, L is absent or selected from S(O 2 )phenyl, succinic acid linker, diamino PEG spacer, amino-PEG-hydroxyl spacer, methylene phenyl, and C(O)NHC 2 H 4 SSC 2 H 4 NHC(O)C 3 H 6 ; Q is selected from N-hydroxysuccinimide (NHS) ester, benzylamine, amine, hydroxyl, 3-methoxycarbonyl, 3-hydroxycarbonyl, 4-methoxycarbonyl, COOH, and ((2,5-dioxopyrrolidin-1-yl)oxy)carbonyl.
3. The compound described in claim 2, wherein the N atom of the compound described in claim 1 is bonded to the functional group (Q) via the optional linker (L).
4. A process for preparing a compound of formula (II) according to claim 1, comprising the steps of: a. converting bishydrazone (2) to iminodidehydrosulfonimino (3); 【Chemistry 2】 b. isolating the resulting iminodidehydrosulfonimino (3); A method comprising:
5. The conversion comprises an oxidation reaction in which the bishydrazone (2) is reacted with an oxidizing agent to oxidize the sulfur functionality to a sulfonimino functionality; 5. The method of claim 4, wherein the conversion further comprises an oxidation reaction in which the bishydrazone (2) is reacted with an oxidizing agent to oxidize the hydrazone functionality to an alkyne functionality.
6. 6. The method of claim 5, wherein the oxidation reaction is a two-step reaction, and the oxidation reaction is a one-pot reaction with one oxidizing agent.
7. The method of claim 6 , wherein the oxidizing agent is iodobenzene diacetate.
Citation Information
Patent Citations
Polymer conjugate for delivering a bioactive agent
JP2016515099A
Compositions and methods for modification of biomolecules
US20090068738A1
Electronically activated strained alkynes
US20180201593A1
